1
|
Shah RR, Shah K, Wilson BN, Leitao MM, Smogorzewski J, Crane C, Funt SA, Hosein S, Dafinone M, Rossi A. Extramammary Paget Disease. Part II. Evidence-based Approach to Management. J Am Acad Dermatol 2024:S0190-9622(24)00579-6. [PMID: 38588817 DOI: 10.1016/j.jaad.2023.07.1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 06/30/2023] [Accepted: 07/09/2023] [Indexed: 04/10/2024]
Abstract
Extramammary Paget disease is a rare cutaneous malignancy that most commonly affects the genitals, perianal area, and axilla of elderly patients. Delays in care often lead to high levels of disease burden for patients. Thus, evidence-based recommendations are paramount in mitigating morbidity and mortality for this unique patient population. This 2-part continuing medical education series provides a complete picture of extramammary Paget disease. Part 2 of this continuing medical education series focuses on the complex management of extramammary Paget disease including surgical and non-invasive therapies, as well as novel approaches for advanced disease.
Collapse
Affiliation(s)
| | - Kalee Shah
- Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York
| | | | - Mario M Leitao
- Department of Gynecology, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Samuel A Funt
- Department of Urologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Sharif Hosein
- Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Anthony Rossi
- Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY.
| |
Collapse
|
2
|
Siddiq S, Murray V, Tyagi N, Borman P, Gui C, Crane C, Wu C, Otazo R. MR signature matching (MRSIGMA) implementation for true real-time free-breathing volumetric imaging with sub-200 ms latency on an MR-Linac. Magn Reson Med 2024. [PMID: 38576131 DOI: 10.1002/mrm.30097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 02/20/2024] [Accepted: 03/14/2024] [Indexed: 04/06/2024]
Abstract
PURPOSE Develop a true real-time implementation of MR signature matching (MRSIGMA) for free-breathing 3D MRI with sub-200 ms latency on the Elekta Unity 1.5T MR-Linac. METHODS MRSIGMA was implemented on an external computer with a network connection to the MR-Linac. Stack-of-stars with partial kz sampling was used to accelerate data acquisition and ReconSocket was employed for simultaneous data transmission. Movienet network computed the 4D MRI motion dictionary and correlation analysis was used for signature matching. A programmable 4D MRI phantom was utilized to evaluate MRSIGMA with respect to a ground-truth translational motion reference. In vivo validation was performed on patients with pancreatic cancer, where 15 patients were employed to train Movienet and 7 patients to test the real-time implementation of MRSIGMA. Dice coefficients between real-time MRSIGMA and a retrospectively computed 4D reference were used to evaluate motion tracking performance. RESULTS Motion dictionary was computed in under 5 s. Signature acquisition and matching presented 173 ms latency on the phantom and 193 ms on patients. MRSIGMA presented a mean error of 1.3-1.6 mm for all phantom experiments, which was below the 2 mm acquisition resolution along the motion direction. The Dice coefficient over time between MRSIGMA and reference contours was 0.88 ± 0.02 (GTV), 0.87 ± 0.02(duodenum-stomach), and 0.78 ± 0.02(small bowel), demonstrating high motion tracking performance for both tumor and organs at risk. CONCLUSION The real-time implementation of MRSIGMA enabled true real-time free-breathing 3D MRI with sub-200 ms imaging latency on a clinical MR-Linac system, which can be used for treatment monitoring, adaptive radiotherapy and dose accumulation mapping in tumors affected by respiratory motion.
Collapse
Affiliation(s)
- Saad Siddiq
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Victor Murray
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Pim Borman
- Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Chengcheng Gui
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Can Wu
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ricardo Otazo
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
3
|
Feferman Y, Rosen R, Gebran S, Yuval JB, Kerioui M, Gonen M, Wei IH, Widmar M, Nash GM, Weiser MR, Paty PB, Hajj C, O’Brien DR, Romesser PB, Crane C, Smith JJ, Aguilar JG, Pappou EP. Anal Adenocarcinoma Treated in the Era of Total Neoadjuvant Therapy and Nonoperative Management. Dis Colon Rectum 2024; 67:496-504. [PMID: 38127627 PMCID: PMC10922541 DOI: 10.1097/dcr.0000000000003113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
BACKGROUND Anal adenocarcinoma bears a treatment strategy unique to other anal cancers. OBJECTIVE This study aimed to describe oncologic outcomes of total neoadjuvant therapy followed by watch-and-wait approach for anal adenocarcinoma. DESIGN Retrospective analysis. SETTINGS This study was conducted at a comprehensive cancer center. PATIENTS Patients with anal adenocarcinoma treated between 2004 and 2019 were selected. INTERVENTIONS Fifty-four patients received neoadjuvant therapy and were divided into 2 groups according to their treatment strategy: total neoadjuvant therapy versus single neoadjuvant modality therapy. MAIN OUTCOME MEASURES Organ preservation, tumor regrowth, local failure, distant metastasis rates, recurrence-free survival, and overall survival. RESULTS This study included 70 patients with anal adenocarcinoma. Fifty-four patients (77%) received neoadjuvant therapy, of whom 30 (42%) received total neoadjuvant therapy and 24 (34%) received single neoadjuvant modality. Twenty-three (33%) patients achieved complete clinical response and were managed by watch-and-wait approach. The proportion of patients able to continue to watch-and-wait approach was higher after receiving total neoadjuvant therapy (60%) compared with single neoadjuvant modality therapy (20%; p = 0.004). A tumor regrowth rate of 22% was observed in the total neoadjuvant therapy group. The 5-year overall survival rate was 70% (95% CI, 59%-83%), including 61% (95% CI, 42%-88%) for the total neoadjuvant therapy and 65% (95% CI, 48%-88%) for the single neoadjuvant modality groups. Colostomy was avoided in 50% of patients who received total neoadjuvant therapy and 83% of watch-and-wait patients. Five-year recurrence-free survival rates of 55% (95% CI, 39%-79%) and 30% (95% CI, 15%-58%) were observed in the total neoadjuvant therapy and single neoadjuvant modality groups. LIMITATIONS Retrospective nature. CONCLUSIONS This is the first report in the literature describing the safety and feasibility of nonoperative management for anal adenocarcinoma. Anal adenocarcinoma treated with total neoadjuvant therapy and nonoperative management achieve regrowth rates comparable to those observed in rectal cancer, with oncologic outcomes similar to those of traditional treatment strategies. See Video Abstract . ADENOCARCINOMA ANAL TRATADO EN LA ERA DE LA TERAPIA NEOADYUVANTE TOTAL Y EL TRATAMIENTO NO QUIRRGICO ANTECEDENTES:El adenocarcinoma anal conlleva una estrategia de tratamiento único para otros cánceres anales.OBJETIVO:Describir los resultados oncológicos de la terapia neoadyuvante total seguida de observar y esperar en adenocarcinoma anal.DISEÑO:Análisis retrospectivo.AJUSTE:Este estudio se llevó a cabo en un centro oncológico integral.PACIENTES:Se seleccionaron pacientes con adenocarcinoma anal tratados entre 2004-2019.INTERVENCIONES:Cincuenta y cuatro pacientes recibieron terapia neoadyuvante y se dividieron en dos grupos según su estrategia de tratamiento: terapia neoadyuvante total versus terapia de modalidad neoadyuvante única.PRINCIPALES MEDIDAS DE RESULTADO:Preservación de órganos, recurrencia tumoral, falla local, tasas de metástasis a distancia, libre de recurrencia y supervivencia general.RESULTADOS:El estudio incluyó a 70 pacientes con adenocarcinoma anal. Cincuenta y cuatro pacientes (77%) recibieron terapia neoadyuvante, de los cuales 30 (42%) recibieron terapia neoadyuvante total y 24 (34%) recibieron modalidad neoadyuvante única. Veintitrés (33%) pacientes presentaron una respuesta clínica completa y fueron tratados con vigilancia y espera. La proporción de pacientes capaces de continuar en observar y esperar fue mayor después de recibir terapia neoadyuvante total (60%) en comparación con la terapia de modalidad neoadyuvante única (20%) ( p = 0,004). Se observó una tasa de recurrencia tumoral del 22% en el grupo de terapia neoadyuvante total. La tasa de supervivencia general a 5 años fue del 70% (IC95% 59%-83 %), incluido el 61% (IC95% 42%-88%) para la terapia neoadyuvante total y el 65% (IC95% 48%-88%) para grupos de modalidad neoadyuvante única. Se evitó la colostomía en el 50% de los pacientes que recibieron terapia neoadyuvante total y el 83% de los pacientes en observar y esperar. Se observaron tasas de supervivencia libre de recurrencia a cinco años del 55% (IC95% 39%-79%) y del 30% (IC95% 15%-58%) en los grupos de terapia neoadyuvante total y modalidad neoadyuvante única, respectivamente.LIMITACIONES:Diseño retrospectivo.CONCLUSIONES:Este es el primer informe en la literatura que describe la seguridad y viabilidad del tratamiento no quirúrgico del adenocarcinoma anal. El adenocarcinoma anal tratado con terapia neoadyuvante total y manejo no quirúrgico logra tasas de recurrencia comparables a las observadas en el cáncer de recto, con resultados oncológicos similares a las estrategias de tratamientos tradicionales. (Traducción-Dr. Fidel Ruiz Healy ).
Collapse
Affiliation(s)
- Yael Feferman
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Roni Rosen
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Selim Gebran
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jonathan B. Yuval
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marion Kerioui
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Mithat Gonen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Iris H. Wei
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Maria Widmar
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Garrett M. Nash
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Martin R. Weiser
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Philip B. Paty
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Carla Hajj
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Diana Roth O’Brien
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Paul B. Romesser
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - J. Joshua Smith
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Julio Garcia Aguilar
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Emmanouil P. Pappou
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
4
|
Shurin MR, Kirichenko VA, Shurin GV, Lee D, Crane C, Kirichenko AV. Radiomodulating Properties of Superparamagnetic Iron Oxide Nanoparticle (SPION) Agent Ferumoxytol on Human Monocytes: Implications for MRI-Guided Liver Radiotherapy. Cancers (Basel) 2024; 16:1318. [PMID: 38610996 PMCID: PMC11011128 DOI: 10.3390/cancers16071318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 03/26/2024] [Accepted: 03/26/2024] [Indexed: 04/14/2024] Open
Abstract
Superparamagnetic iron oxide nanoparticles (SPION) have attracted great attention not only for therapeutic applications but also as an alternative magnetic resonance imaging (MRI) contrast agent that helps visualize liver tumors during MRI-guided stereotactic body radiotherapy (SBRT). SPION can provide functional imaging of liver parenchyma based upon its uptake by the hepatic resident macrophages or Kupffer cells with a relative enhancement of malignant tumors that lack Kupffer cells. However, the radiomodulating properties of SPION on liver macrophages are not known. Utilizing human monocytic THP-1 undifferentiated and differentiated cells, we characterized the effect of ferumoxytol (Feraheme®), a carbohydrate-coated ultrasmall SPION agent at clinically relevant concentration and therapeutically relevant doses of gamma radiation on cultured cells in vitro. We showed that ferumoxytol affected both monocytes and macrophages, increased the resistance of monocytes to radiation-induced cell death and inhibition of cell activity, and supported the anti-inflammatory phenotype of human macrophages under radiation. Its effect on human cells depended on the duration of SPION uptake and was radiation dose-dependent. The results of this pilot study support a strong mechanism-based optimization of SPION-enhanced MRI-guided liver SBRT for primary and metastatic liver tumors, especially in patients with liver cirrhosis awaiting a liver transplant.
Collapse
Affiliation(s)
- Michael R. Shurin
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA;
| | - Vladimir A. Kirichenko
- Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA; (V.A.K.); (D.L.)
| | - Galina V. Shurin
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA;
| | - Danny Lee
- Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA; (V.A.K.); (D.L.)
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
| | - Alexander V. Kirichenko
- Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA; (V.A.K.); (D.L.)
| |
Collapse
|
5
|
Fernandes EAF, van Oudtshoorn J, Tam A, González LCA, Aurela EG, Potthast H, Mettke K, Kuribayashi R, Shimojo K, Kasuga M, Morales L, Rodríguez Z, Jones B, Ahn C, Yun E, Kim SH, Rodrigues C, Tiong T, Crane C, Walther C, Roost MS, Chen TL, Hsu LF, Braddy AC, García-Arieta A, Abalos I, Divinsky M, Alsuwyeh A, Alzenaidy B, Alharf A. The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities. J Pharm Pharm Sci 2024; 27:12398. [PMID: 38577255 PMCID: PMC10993868 DOI: 10.3389/jpps.2024.12398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Accepted: 02/23/2024] [Indexed: 04/06/2024]
Abstract
Bioequivalence (BE) studies are considered the standard for demonstrating that the performance of a generic drug product in the human body is sufficiently similar to that of its comparator product. The objective of this article is to describe the recommendations from participating Bioequivalence Working Group for Generics (BEWGG) members of the International Pharmaceutical Regulators Programme (IPRP) regarding the conduct and acceptance criteria for BE studies of immediate release solid oral dosage forms. A survey was conducted among BEWGG members regarding their BE recommendations and requirements related to study subjects, study design, sample size, single or multiple dose administration, study conditions (fasting or fed), analyte to be measured, selection of product strength, drug content, handling of endogenous substances, BE acceptance criteria, and additional design aspects. All members prefer conducting single dose cross-over designed studies in healthy subjects with a minimum of 12 subjects and utilizing the parent drug data to assess BE. However, differences emerged among the members when the drug's pharmacokinetics and pharmacodynamics become more complex, such that the study design (e.g., fasting versus fed conditions) and BE acceptance criteria (e.g., highly variable drugs, narrow therapeutic index drugs) may be affected. The survey results and discussions were shared with the ICH M13 Expert Working Group (EWG) and played an important role in identifying and analyzing gaps during the harmonization process. The draft ICH M13A guideline developed by the M13 EWG was endorsed by ICH on 20 December 2022, under Step 2.
Collapse
Affiliation(s)
| | - Joy van Oudtshoorn
- South African Health Products Regulatory Authority, Pretoria, South Africa
| | | | | | - Erwin Guzmán Aurela
- Instituto Nacional de Vigilancia de Medicamentos y Alimentos, Bogota, Colombia
| | | | - Katalina Mettke
- Federal Institute for Drugs and Medical Devices, Bonn, Germany
| | - Ryosuke Kuribayashi
- Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
| | - Kohei Shimojo
- Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
| | - Miho Kasuga
- Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
| | - Lázaro Morales
- Comisión Federal para la Protección contra Riesgos Sanitarios, Ciudad de Mexico, México
| | - Zulema Rodríguez
- Comisión Federal para la Protección contra Riesgos Sanitarios, Ciudad de Mexico, México
| | | | - Choongyul Ahn
- Ministry of Food and Drug Safety, Cheongju-si, Republic of Korea
| | - Eunju Yun
- Ministry of Food and Drug Safety, Cheongju-si, Republic of Korea
| | - So Hee Kim
- Ministry of Food and Drug Safety, Cheongju-si, Republic of Korea
| | | | - Toh Tiong
- Health Sciences Authority, Singapore, Singapore
| | | | | | | | | | | | - April C. Braddy
- Food and Drug Administration, Silver Spring, MD, United States
| | - Alfredo García-Arieta
- WHO-Observer, Geneva, Switzerland
- Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
| | - Ivana Abalos
- Administración Nacional de Medicamentos, Alimentos y Tecnología, Buenos Aires, Argentina
| | - Milly Divinsky
- Center for Pharmaceutical and Enforcement Division, Jerusalem, Israel
| | | | | | - Adel Alharf
- Saudi Food and Drug Authority, Riyadh, Saudi Arabia
| |
Collapse
|
6
|
Murray V, Siddiq S, Crane C, El Homsi M, Kim TH, Wu C, Otazo R. Movienet: Deep space-time-coil reconstruction network without k-space data consistency for fast motion-resolved 4D MRI. Magn Reson Med 2024; 91:600-614. [PMID: 37849064 PMCID: PMC10842259 DOI: 10.1002/mrm.29892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/19/2023]
Abstract
PURPOSE To develop a novel deep learning approach for 4D-MRI reconstruction, named Movienet, which exploits space-time-coil correlations and motion preservation instead of k-space data consistency, to accelerate the acquisition of golden-angle radial data and enable subsecond reconstruction times in dynamic MRI. METHODS Movienet uses a U-net architecture with modified residual learning blocks that operate entirely in the image domain to remove aliasing artifacts and reconstruct an unaliased motion-resolved 4D image. Motion preservation is enforced by sorting the input image and reference for training in a linear motion order from expiration to inspiration. The input image was collected with a lower scan time than the reference XD-GRASP image used for training. Movienet is demonstrated for motion-resolved 4D MRI and motion-resistant 3D MRI of abdominal tumors on a therapeutic 1.5T MR-Linac (1.5-fold acquisition acceleration) and diagnostic 3T MRI scanners (2-fold and 2.25-fold acquisition acceleration for 4D and 3D, respectively). Image quality was evaluated quantitatively and qualitatively by expert clinical readers. RESULTS The reconstruction time of Movienet was 0.69 s (4 motion states) and 0.75 s (10 motion states), which is substantially lower than iterative XD-GRASP and unrolled reconstruction networks. Movienet enables faster acquisition than XD-GRASP with similar overall image quality and improved suppression of streaking artifacts. CONCLUSION Movienet accelerates data acquisition with respect to compressed sensing and reconstructs 4D images in less than 1 s, which would enable an efficient implementation of 4D MRI in a clinical setting for fast motion-resistant 3D anatomical imaging or motion-resolved 4D imaging.
Collapse
Affiliation(s)
- Victor Murray
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Syed Siddiq
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Maria El Homsi
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Tae-Hyung Kim
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Can Wu
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ricardo Otazo
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
7
|
Chami P, Diab Y, Khalil DN, Azhari H, Jarnagin WR, Abou-Alfa GK, Harding JJ, Hajj J, Ma J, El Homsi M, Reyngold M, Crane C, Hajj C. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2023; 24:16773. [PMID: 38069095 PMCID: PMC10706661 DOI: 10.3390/ijms242316773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 11/24/2023] [Accepted: 11/24/2023] [Indexed: 12/18/2023] Open
Abstract
The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, for several types of cancers, including HCC, liver metastases have shown evidence of resistance or poor response to immunotherapies. Radiation therapy (RT) has displayed evidence of immunosuppressive effects through the upregulation of immune checkpoint molecules post-treatment. However, it was revealed that the limitations of ICIs can be overcome through the use of RT, as it can reshape the liver immune microenvironment. Moreover, ICIs are able to overcome the RT-induced inhibitory signals, effectively restoring anti-tumor activity. Owing to the synergetic effect believed to arise from the combination of ICIs with RT, several clinical trials are currently ongoing to assess the efficacy and safety of this treatment for patients with HCC.
Collapse
Affiliation(s)
- Perla Chami
- Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon;
| | - Youssef Diab
- Faculty of Medicine, University of Balamand, Beirut 1100, Lebanon; (Y.D.)
| | - Danny N. Khalil
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
| | - Hassan Azhari
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
| | - William R. Jarnagin
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
- Department of Surgery, Weill Medical College, Cornell University, New York, NY 10021, USA
| | - Ghassan K. Abou-Alfa
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
- Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA
| | - James J. Harding
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
- Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA
| | - Joseph Hajj
- Faculty of Medicine, University of Balamand, Beirut 1100, Lebanon; (Y.D.)
| | - Jennifer Ma
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
| | - Maria El Homsi
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
| | - Marsha Reyngold
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
| | | | - Carla Hajj
- Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA
- New York Proton Center, New York, NY 10035, USA
| |
Collapse
|
8
|
Wu C, Murray V, Siddiq SS, Tyagi N, Reyngold M, Crane C, Otazo R. Real-time 4D MRI using MR signature matching (MRSIGMA) on a 1.5T MR-Linac system. Phys Med Biol 2023; 68:10.1088/1361-6560/acf3cc. [PMID: 37619588 PMCID: PMC10513779 DOI: 10.1088/1361-6560/acf3cc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Accepted: 08/24/2023] [Indexed: 08/26/2023]
Abstract
Objective. To develop real-time 4D MRI using MR signature matching (MRSIGMA) for volumetric motion imaging in patients with pancreatic cancer on a 1.5T MR-Linac system.Approach. Two consecutive MRI scans with 3D golden-angle radial stack-of-stars acquisitions were performed on ten patients with inoperable pancreatic cancer. The complete first scan (905 angles) was used to compute a 4D motion dictionary including ten pairs of 3D motion images and signatures. The second scan was used for real-time imaging, where each angle (275 ms) was processed separately to match it to one of the dictionary entries. The complete second scan was also used to compute a 4D reference to assess motion tracking performance.Dicecoefficients of the gross tumor volume (GTV) and two organs-at-risk (duodenum-stomach and small bowel) were calculated between signature matching and reference. In addition, volume changes, displacements, center of mass shifts, andDicescores over time were calculated to characterize motion.Main results. Total imaging latency of MRSIGMA (acquisition + matching) was less than 300 ms. TheDicecoefficients were 0.87 ± 0.06 (GTV), 0.86 ± 0.05 (duodenum-stomach), and 0.85 ± 0.05 (small bowel), which indicate high accuracy (high mean value) and low uncertainty (low standard deviation) of MRSIGMA for real-time motion tracking. The center of mass shift was 3.1 ± 2.0 mm (GTV), 5.3 ± 3.0 mm (duodenum-stomach), and 3.4 ± 1.5 mm (small bowel). TheDicescores over time (0.97 ± [0.01-0.03]) were similarly high for MRSIGMA and reference scans in all the three contours.Significance. This work demonstrates the feasibility of real-time 4D MRI using MRSIGMA for volumetric motion tracking on a 1.5T MR-Linac system. The high accuracy and low uncertainty of real-time MRSIGMA is an essential step towards continuous treatment adaptation of tumors affected by real-time respiratory motion and could ultimately improve treatment safety by optimizing ablative dose delivery near gastrointestinal organs.
Collapse
Affiliation(s)
- Can Wu
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Victor Murray
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Syed S. Siddiq
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Marsha Reyngold
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Ricardo Otazo
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
9
|
Jiang J, Hong J, Tringale K, Reyngold M, Crane C, Tyagi N, Veeraraghavan H. Progressively refined deep joint registration segmentation (ProRSeg) of gastrointestinal organs at risk: Application to MRI and cone-beam CT. Med Phys 2023; 50:4758-4774. [PMID: 37265185 PMCID: PMC11009869 DOI: 10.1002/mp.16527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 04/27/2023] [Accepted: 05/08/2023] [Indexed: 06/03/2023] Open
Abstract
BACKGROUND Adaptive radiation treatment (ART) for locally advanced pancreatic cancer (LAPC) requires consistently accurate segmentation of the extremely mobile gastrointestinal (GI) organs at risk (OAR) including the stomach, duodenum, large and small bowel. Also, due to lack of sufficiently accurate and fast deformable image registration (DIR), accumulated dose to the GI OARs is currently only approximated, further limiting the ability to more precisely adapt treatments. PURPOSE Develop a 3-D Progressively refined joint Registration-Segmentation (ProRSeg) deep network to deformably align and segment treatment fraction magnetic resonance images (MRI)s, then evaluate segmentation accuracy, registration consistency, and feasibility for OAR dose accumulation. METHOD ProRSeg was trained using five-fold cross-validation with 110 T2-weighted MRI acquired at five treatment fractions from 10 different patients, taking care that same patient scans were not placed in training and testing folds. Segmentation accuracy was measured using Dice similarity coefficient (DSC) and Hausdorff distance at 95th percentile (HD95). Registration consistency was measured using coefficient of variation (CV) in displacement of OARs. Statistical comparison to other deep learning and iterative registration methods were done using the Kruskal-Wallis test, followed by pair-wise comparisons with Bonferroni correction applied for multiple testing. Ablation tests and accuracy comparisons against multiple methods were done. Finally, applicability of ProRSeg to segment cone-beam CT (CBCT) scans was evaluated on a publicly available dataset of 80 scans using five-fold cross-validation. RESULTS ProRSeg processed 3D volumes (128 × 192 × 128) in 3 s on a NVIDIA Tesla V100 GPU. It's segmentations were significantly more accurate (p < 0.001 $p<0.001$ ) than compared methods, achieving a DSC of 0.94 ±0.02 for liver, 0.88±0.04 for large bowel, 0.78±0.03 for small bowel and 0.82±0.04 for stomach-duodenum from MRI. ProRSeg achieved a DSC of 0.72±0.01 for small bowel and 0.76±0.03 for stomach-duodenum from public CBCT dataset. ProRSeg registrations resulted in the lowest CV in displacement (stomach-duodenumC V x $CV_{x}$ : 0.75%,C V y $CV_{y}$ : 0.73%, andC V z $CV_{z}$ : 0.81%; small bowelC V x $CV_{x}$ : 0.80%,C V y $CV_{y}$ : 0.80%, andC V z $CV_{z}$ : 0.68%; large bowelC V x $CV_{x}$ : 0.71%,C V y $CV_{y}$ : 0.81%, andC V z $CV_{z}$ : 0.75%). ProRSeg based dose accumulation accounting for intra-fraction (pre-treatment to post-treatment MRI scan) and inter-fraction motion showed that the organ dose constraints were violated in four patients for stomach-duodenum and for three patients for small bowel. Study limitations include lack of independent testing and ground truth phantom datasets to measure dose accumulation accuracy. CONCLUSIONS ProRSeg produced more accurate and consistent GI OARs segmentation and DIR of MRI and CBCTs compared to multiple methods. Preliminary results indicates feasibility for OAR dose accumulation using ProRSeg.
Collapse
Affiliation(s)
- Jue Jiang
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Jun Hong
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Kathryn Tringale
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Marsha Reyngold
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Harini Veeraraghavan
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|
10
|
Miller E, Crane C, Medlicott E, Robson J, Taylor L. Non-Positive Experiences Encountered by Pupils During Participation in a Mindfulness-Informed School-Based Intervention. School Ment Health 2023; 15:851-872. [PMID: 37720164 PMCID: PMC10504121 DOI: 10.1007/s12310-023-09591-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/16/2023] [Indexed: 09/19/2023]
Abstract
Mindfulness-informed school-based mental health curricula show much promise in cultivating a positive school climate which supports the well-being and mental health of pupils and staff. However, non-positive pupil outcomes and experiences of school-based mental health interventions are often under-recognised and under-reported. This study sought to capture non-positive pupil experiences of a popular mindfulness-informed curriculum. Some pupils across all schools in the study described non-positive experiences, including having troubling thoughts and emotions, and not finding the programme effective. Contexts surrounding these experiences are explored and linked to existing literature, and subsequent recommendations for improvements are made, including the importance of having clear programme structure, definitions and aims, acknowledging and accommodating fidelity issues as best as possible, and better highlighting the potential for non-positive experiences and how they may be reduced.
Collapse
Affiliation(s)
- E.J. Miller
- University of Auckland, Auckland, New Zealand
- University of Oxford, Oxford, UK
| | - C. Crane
- University of Oxford, Oxford, UK
- OxfordHealth NHS Foundation Trust, Oxford, UK
| | | | | | | |
Collapse
|
11
|
Lindenmayer DB, Blanchard W, Evans MJ, Beggs R, Lavery T, Florance D, Crane C, Smith D, Siegrist A, Lang E, Scheele BC. Context dependency in interference competition among birds in an endangered woodland ecosystem. DIVERS DISTRIB 2023. [DOI: 10.1111/ddi.13680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Affiliation(s)
- D. B. Lindenmayer
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - W. Blanchard
- Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - M. J. Evans
- Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - R. Beggs
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - T. Lavery
- Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - D. Florance
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - C. Crane
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - D. Smith
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - A. Siegrist
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - E. Lang
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| | - B. C. Scheele
- Sustainable Farms, Fenner School of Environment & Society The Australian National University Canberra Australian Capital Territory Australia
| |
Collapse
|
12
|
Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, Keane F, Balogun F, Yu KH, Kelsen DP, Crane C, Capanu M, Iacobuzio-Donahue C, O'Reilly EM. Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. Clin Cancer Res 2022; 28:4782-4792. [PMID: 36040493 PMCID: PMC9634347 DOI: 10.1158/1078-0432.ccr-22-1483] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Revised: 07/02/2022] [Accepted: 08/26/2022] [Indexed: 01/24/2023]
Abstract
PURPOSE Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL DESIGN Clinico-genomic data for patients with PDAC and other cancers with ATM variants were abstracted. Genomic instability scores (GIS) were derived from ATM-mutant cancers and overall survival (OS) was evaluated. RESULTS Forty-six patients had PDAC and pathogenic ATM variants including 24 (52%) stage III/IV: gATMm (N = 24), and sATMm (N = 22). Twenty-seven (59%) had biallelic, 15 (33%) monoallelic, and 4 indeterminate (8%) variants. Median OS for advanced-stage cohort at diagnosis (N = 24) was 19.7 months [95% confidence interval (CI): 12.3-not reached (NR)], 27.1 months (95% CI: 22.7-NR) for gATMm (n = 11), and 12.3 months for sATMm (n = 13; 95% CI: 11.9-NR; P = 0.025). GIS was computed for 33 patients with PDAC and compared with other ATM-mutant cancers enriched for HRD. The median was lower (median, 11; range, 2-29) relative to breast (18, 3-55) or ovarian (25, 3-56) ATM-mutant cancers (P < 0.001 and P = 0.003, respectively). Interestingly, biallelic pathogenic ATM variants were mutually exclusive with TP53. Other canonical driver gene (KRAS, CDKN2A, SMAD4) variants were less frequent in ATM-mutant PDAC. CONCLUSIONS ATM variants in PDAC represent a distinct biologic group and appear to have favorable OS. Nonetheless, pathogenic ATM variants do not confer an HRD signature in PDAC and ATM should be considered as a non-core HR gene in this disease.
Collapse
Affiliation(s)
- Wungki Park
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- Weill Cornell Medicine, New York, New York
- Parker Institute of Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Catherine A O'Connor
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Chaitanya Bandlamudi
- Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Daniella Forman
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Joanne F Chou
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Shigeaki Umeda
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
- Human Oncology Pathogenesis Program, Sloan Kettering Institute, New York, New York
| | - Marsha Reyngold
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Anna M Varghese
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Fergus Keane
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Fiyinfolu Balogun
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Kenneth H Yu
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| | - David P Kelsen
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christopher Crane
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marinela Capanu
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christine Iacobuzio-Donahue
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
- Human Oncology Pathogenesis Program, Sloan Kettering Institute, New York, New York
| | - Eileen M O'Reilly
- Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
- Weill Cornell Medicine, New York, New York
- David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
13
|
Hong J, Reyngold M, Crane C, Cuaron J, Hajj C, Mann J, Zinovoy M, Yorke E, LoCastro E, Apte AP, Mageras G. CT and cone-beam CT of ablative radiation therapy for pancreatic cancer with expert organ-at-risk contours. Sci Data 2022; 9:637. [PMID: 36271000 PMCID: PMC9587208 DOI: 10.1038/s41597-022-01758-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Accepted: 10/04/2022] [Indexed: 11/15/2022] Open
Abstract
We describe a dataset from patients who received ablative radiation therapy for locally advanced pancreatic cancer (LAPC), consisting of computed tomography (CT) and cone-beam CT (CBCT) images with physician-drawn organ-at-risk (OAR) contours. The image datasets (one CT for treatment planning and two CBCT scans at the time of treatment per patient) were collected from 40 patients. All scans were acquired with the patient in the treatment position and in a deep inspiration breath-hold state. Six radiation oncologists delineated the gastrointestinal OARs consisting of small bowel, stomach and duodenum, such that the same physician delineated all image sets belonging to the same patient. Two trained medical physicists further edited the contours to ensure adherence to delineation guidelines. The image and contour files are available in DICOM format and are publicly available from The Cancer Imaging Archive (10.7937/TCIA.ESHQ-4D90, Version 2). The dataset can serve as a criterion standard for evaluating the accuracy and reliability of deformable image registration and auto-segmentation algorithms, as well as a training set for deep-learning-based methods. Measurement(s) | Image Segmentation • Stomach • Duodenum • Small Intestine | Technology Type(s) | Computed Tomography • Kilovoltage Cone Beam Computed Tomography • Manual | Factor Type(s) | Treatment planning dose | Sample Characteristic - Organism | Homo sapiens |
Collapse
Affiliation(s)
- Jun Hong
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Marsha Reyngold
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - John Cuaron
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Carla Hajj
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Justin Mann
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Melissa Zinovoy
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Ellen Yorke
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Eve LoCastro
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Aditya P Apte
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Gig Mageras
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
| |
Collapse
|
14
|
Tam A, Garcia-Arieta A, Abalos I, Agostinho Freitas Fernandes E, Mendes Lima Santos G, Rodriguez Martinez Z, Divinsky M, Kariv R, Potthast H, Braddy AC, Rodrigues C, Guzman Aurela E, Carolina Arevalo Gonzalez L, Gutierres Triana D, Jones B, Ahn C, Kim H, Kim SH, Kuribayashi R, Myoenzono A, Shimojo K, Van Oudtshoorn J, Bigler C, Meincke R, Roost MS, Walther C, Hsu LF, Crane C, Jarman T. A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme. J Pharm Pharm Sci 2022; 25:323-339. [DOI: 10.18433/jpps33081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The safety and efficacy of a generic product are partly based on demonstrating bioequivalence to the innovator product; however, when the innovator product is no longer available as a comparator product, a survey conducted within the Bioequivalence Working Group for Generics (BEWGG) of the International Pharmaceutical Regulators Programme (IPRP) indicated that the criteria for selecting an alternative comparator product varies. For most members of the BEWGG, an existing marketed generic that was approved based on a comparison with the locally registered innovator product can be used, contingent on criteria that ranges from allowing any generic to be used, to allowing only specific criteria-defined generics to be used. Notwithstanding the acceptability of a generic as an alternative comparator, it is not always the preferred comparator for several jurisdictions. Some jurisdictions require the use of a locally sourced alternative innovator comparator (e.g., the same medicinal ingredient manufactured by a different company) or a foreign innovator comparator. Unlike the other members of the BEWGG, the European Union (EU) has no such options available, rather mechanisms are in place to allow manufacturers to develop a new comparator. The criteria described herein regarding the use of an alternative comparator product can also be applied to scenarios where a specific strength of a series of strengths or an innovative fixed dose combination are discontinued. The results of the survey demonstrate that while criteria for selecting alternative comparator products are not harmonized among the BEWGG participants, the common concern for all jurisdictions is to select a comparator product that meets the safety and efficacy standards of the original innovator product.
Collapse
|
15
|
Jiang J, Tyagi N, Tringale K, Crane C, Veeraraghavan H. Self-supervised 3D anatomy segmentation using self-distilled masked image transformer (SMIT). Med Image Comput Comput Assist Interv 2022; 13434:556-566. [PMID: 36468915 PMCID: PMC9714226 DOI: 10.1007/978-3-031-16440-8_53] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Vision transformers efficiently model long-range context and thus have demonstrated impressive accuracy gains in several image analysis tasks including segmentation. However, such methods need large labeled datasets for training, which is hard to obtain for medical image analysis. Self-supervised learning (SSL) has demonstrated success in medical image segmentation using convolutional networks. In this work, we developed a self-distillation learning with masked image modeling method to perform SSL for vision transformers (SMIT) applied to 3D multi-organ segmentation from CT and MRI. Our contribution combines a dense pixel-wise regression pretext task performed within masked patches called masked image prediction with masked patch token distillation to pre-train vision transformers. Our approach is more accurate and requires fewer fine tuning datasets than other pretext tasks. Unlike prior methods, which typically used image sets arising from disease sites and imaging modalities corresponding to the target tasks, we used 3,643 CT scans (602,708 images) arising from head and neck, lung, and kidney cancers as well as COVID-19 for pre-training and applied it to abdominal organs segmentation from MRI pancreatic cancer patients as well as publicly available 13 different abdominal organs segmentation from CT. Our method showed clear accuracy improvement (average DSC of 0.875 from MRI and 0.878 from CT) with reduced requirement for fine-tuning datasets over commonly used pretext tasks. Extensive comparisons against multiple current SSL methods were done. Our code is available at: https://github.com/harveerar/SMIT.git.
Collapse
Affiliation(s)
- Jue Jiang
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center
| | - Kathryn Tringale
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center
| | | |
Collapse
|
16
|
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022; 386:2363-2376. [PMID: 35660797 PMCID: PMC9492301 DOI: 10.1056/nejmoa2201445] [Citation(s) in RCA: 481] [Impact Index Per Article: 240.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer. METHODS We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy. RESULTS A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported. CONCLUSIONS Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.).
Collapse
Affiliation(s)
- Andrea Cercek
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Melissa Lumish
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Jenna Sinopoli
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Jill Weiss
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Jinru Shia
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Michelle Lamendola-Essel
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Imane H El Dika
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Neil Segal
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Marina Shcherba
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Ryan Sugarman
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Zsofia Stadler
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Rona Yaeger
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - J Joshua Smith
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Benoit Rousseau
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Guillem Argiles
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Miteshkumar Patel
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Avni Desai
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Leonard B Saltz
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Maria Widmar
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Krishna Iyer
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Janie Zhang
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Nicole Gianino
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Christopher Crane
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Paul B Romesser
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Emmanouil P Pappou
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Philip Paty
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Julio Garcia-Aguilar
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Mithat Gonen
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Marc Gollub
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Martin R Weiser
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Kurt A Schalper
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| | - Luis A Diaz
- From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan Kettering Cancer Center, New York; and the Department of Pathology, Yale University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.)
| |
Collapse
|
17
|
Deck JW, Cavanagh L, Crane C, Perkins FT, Jarrett C, Hoberecht T. Thumb Spica Casts for Scaphoid Fractures. Am Fam Physician 2022; 105:307-308. [PMID: 35289577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- Jason W Deck
- University of Oklahoma School of Community Medicine, Tulsa, OK, USA
| | - Lamont Cavanagh
- University of Oklahoma School of Community Medicine, Tulsa, OK, USA
| | | | | | | | - Toni Hoberecht
- Schusterman Library, University of Oklahoma-Tulsa, Tulsa, OK, USA
| |
Collapse
|
18
|
Hall WA, Dawson LA, Hong TS, Palta M, Herman JM, Evans DB, Tsai S, Ferrone CR, B. Fleming J, Chang DT, Crane C, Koong AC, Oar A, Parikh P, Erickson B, Hoffe S, Goodman KA. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. J Clin Oncol 2021; 39:3773-3777. [PMID: 34623894 PMCID: PMC8608256 DOI: 10.1200/jco.21.01220] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 08/10/2021] [Accepted: 09/09/2021] [Indexed: 12/12/2022] Open
Affiliation(s)
- William A. Hall
- Medical College of Wisconsin, Department of Radiation Oncology and the LaBahn Pancreatic Cancer Program, Milwaukee, WI
- Medical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI
| | - Laura A. Dawson
- Radiation Medicine Program, Princess Margaret Cancer Centre; Department of Radiation Oncology, University of Toronto, Toronto, Canada
| | - Theodore S. Hong
- Massachusetts General Hospital, Department of Radiation Oncology, Boston, MA
| | - Manisha Palta
- Duke University, Department of Radiation Oncology, Durham, NC
| | - Joseph M. Herman
- Northwell Health, Department of Radiation Oncology, New Hyde Park, NY
| | - Douglas B. Evans
- Medical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI
| | - Susan Tsai
- Medical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI
| | | | | | - Daniel T. Chang
- Stanford Health Care, Department of Radiation Oncology, Stanford, CA
| | - Christopher Crane
- Memorial Sloan-Kettering Cancer Center, Department of Radiation Oncology, New York, NY
| | - Albert C. Koong
- MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX
| | - Andrew Oar
- Gold Coast University Hospital, Gold Coast, Queensland, Australia
| | - Parag Parikh
- Henry Ford Health System, Department of Radiation Oncology, Detroit, MI
| | - Beth Erickson
- Medical College of Wisconsin, Department of Radiation Oncology and the LaBahn Pancreatic Cancer Program, Milwaukee, WI
- Medical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI
| | - Sarah Hoffe
- Moffitt Cancer Center, Department of Surgery, Tampa, FL
| | - Karyn A. Goodman
- Mount Sinai Hospital, Department of Radiation Oncology, New York, NY
| |
Collapse
|
19
|
Slevin F, Aitken K, Alongi F, Arcangeli S, Chadwick E, Chang AR, Cheung P, Crane C, Guckenberger M, Jereczek-Fossa BA, Kamran SC, Kinj R, Loi M, Mahadevan A, Massaccesi M, Mendez LC, Muirhead R, Pasquier D, Pontoriero A, Spratt DE, Tsang YM, Zelefsky MJ, Lilley J, Dickinson P, Hawkins MA, Henry AM, Murray LJ. An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. Radiother Oncol 2021; 164:104-114. [PMID: 34560186 DOI: 10.1016/j.radonc.2021.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/08/2021] [Accepted: 09/12/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat metastatic oligorecurrence and locoregional recurrences but limited evidence/guidance exists in the setting of pelvic re-irradiation. An international Delphi study was performed to develop statements to guide practice regarding patient selection, pre-treatment investigations, treatment planning, delivery and cumulative organs at risk (OARs) constraints. MATERIALS AND METHODS Forty-one radiation oncologists were invited to participate in three online surveys. In Round 1, information and opinion was sought regarding participants' practice. Guidance statements were developed using this information and in Round 2 participants were asked to indicate their level of agreement with each statement. Consensus was defined as ≥75% agreement. In Round 3, any statements without consensus were re-presented unmodified, alongside a summary of comments from Round 2. RESULTS Twenty-three radiation oncologists participated in Round 1 and, of these, 21 (91%) and 22 (96%) completed Rounds 2 and 3 respectively. Twenty-nine of 44 statements (66%) achieved consensus in Round 2. The remaining 15 statements (34%) did not achieve further consensus in Round 3. Consensus was achieved for 10 of 17 statements (59%) regarding patient selection/pre-treatment investigations; 12 of 13 statements (92%) concerning treatment planning and delivery; and 7 of 14 statements (50%) relating to OARs. Lack of agreement remained regarding the minimum time interval between irradiation courses, the number/size of pelvic lesions that can be treated and the most appropriate cumulative OAR constraints. CONCLUSIONS This study has established consensus, where possible, in areas of patient selection, pre-treatment investigations, treatment planning and delivery for pelvic SABR re-irradiation for metastatic oligorecurrence and locoregional recurrences. Further research into this technique is required, especially regarding aspects of practice where consensus was not achieved.
Collapse
Affiliation(s)
- Finbar Slevin
- Leeds Teaching Hospitals NHS Trust, UK; University of Leeds, UK.
| | - Katharine Aitken
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
| | - Filippo Alongi
- IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy; University of Brescia, Italy.
| | - Stefano Arcangeli
- School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy.
| | | | - Ah Ram Chang
- Department of Radiation Oncology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
| | | | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloane Kettering Cancer Centre, New York, USA.
| | - Matthias Guckenberger
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.
| | - Barbara Alicja Jereczek-Fossa
- Department of Oncology and Hemato-oncology, University of Milan, Italy; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy.
| | - Sophia C Kamran
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
| | - Rémy Kinj
- Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Mauro Loi
- Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy.
| | - Anand Mahadevan
- Geisinger Medical Center - Radiation Oncology, Danville, USA.
| | - Mariangela Massaccesi
- Dipartimento Diagnostica per Immagini, Radioterapia Oncologica e Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli, Roma, Italy.
| | - Lucas C Mendez
- Division of Radiation Oncology, London Health Sciences Centre, Canada.
| | | | - David Pasquier
- Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France; CRIStAL, UMR 9181, Lille University, Lille, France.
| | - Antonio Pontoriero
- Department of BIOMORF, Radiation Oncology Unit, University of Messina, Italy.
| | - Daniel E Spratt
- Department of Radiation Oncology, University Hospitals Seidman Cancer Centre, Cleveland, USA.
| | | | - Michael J Zelefsky
- Department of Radiation Oncology, Memorial Sloane Kettering Cancer Centre, New York, USA.
| | | | | | - Maria A Hawkins
- Medical Physics and Biochemical Engineering, University College London, UK.
| | - Ann M Henry
- Leeds Teaching Hospitals NHS Trust, UK; University of Leeds, UK.
| | - Louise J Murray
- Leeds Teaching Hospitals NHS Trust, UK; University of Leeds, UK.
| |
Collapse
|
20
|
Roost MS, Potthast H, Walther C, García-Arieta A, Abalos I, Agostinho Freitas Fernandes E, Mendes Lima Santos G, Rodríguez Martínez Z, Tam A, Rodrigues C, Gutierrez Triana DA, Guzmán Aurela E, Rodríguez Rodríguez N, Aeh Park S, Kim J, Kariv R, Divinsky M, Jones B, Kuribayashi R, Myoenzono A, Kasuga M, Van Oudtshoorn J, Chi JF, Hung WY, Hsu LF, Crane C, Jarman T, Braddy A. Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities. J Pharm Pharm Sci 2021; 24:548-562. [PMID: 34706215 DOI: 10.18433/jpps32260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
This article describes an overview of waivers of in vivo bioequivalence studies for additional strengths in the context of the registration of modified release generic products and is a follow-up to the recent publication for the immediate release solid oral dosage forms. The current paper is based on a survey among the participating members of the Bioequivalence Working Group for Generics (BEWGG) of the International Pharmaceutical Regulators Program (IPRP) regarding this topic. Most jurisdictions consider the extrapolation of bioequivalence results obtained with one (most sensitive) strength of a product series as less straightforward for modified release products than for immediate release products. There is consensus that modified release products should demonstrate bioequivalence not only in the fasted state but also in the fed state, but differences exist regarding the necessity of additional multiple dose studies. Fundamental differences between jurisdictions are revealed regarding requirements on the quantitative composition of different strengths and the differentiation of single and multiple unit dosage forms. Differences in terms of in vitro dissolution requirements are obvious, though these are mostly related to possible additional comparative investigations rather than regarding the need for product-specific methods. As with the requirements for immediate release products, harmonization of the various regulations for modified release products is highly desirable to conduct the appropriate studies from a scientific point of view, thus ensuring therapeutic equivalence.
Collapse
Affiliation(s)
| | - Henrike Potthast
- 2European Medicines Agency's (EMA) Pharmacokinetics Working Party and Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bonn, Germany
| | - Chantal Walther
- Swissmedic, Schweizerisches Heilmittelinstitut, Bern, Switzerland
| | - Alfredo García-Arieta
- WHO Prequalification of Medicines Programme, and Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain
| | - Ivana Abalos
- Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), Ciudad Autónoma de Buenos Aires, Argentina
| | | | - Gustavo Mendes Lima Santos
- Agência Nacional de Vigilância Sanitária (ANVISA), Brasília, Brazil; 8Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Ciudad de México, Mexico
| | | | | | - Clare Rodrigues
- Health Sciences Authority, Health Products Regulation Group, Pre-Marketing Cluster, Therapeutic Products Branch, Singapore, Singapore
| | | | - Erwin Guzmán Aurela
- Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Bogotá. Colombia
| | | | - Sang Aeh Park
- Ministry of Food and Drug Safety, Osong-eup Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
| | - Jayoung Kim
- Ministry of Food and Drug Safety, Osong-eup Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea
| | - Rami Kariv
- Ministry of Health (Israel), Pharmaceutical Division, Jerusalem
| | - Milly Divinsky
- Ministry of Health (Israel), Pharmaceutical Division, Jerusalem
| | - Ben Jones
- New Zealand Medicines and Medical Devices Safety Authority (Medsafe), Ministry of Health, Thorndon, Wellington, New Zealand
| | - Ryosuke Kuribayashi
- Pharmaceuticals and Medical Devices Agency (PMDA), Kasumigaseki, Chiyoda-ku, Tokyo, Japan
| | - Aya Myoenzono
- Pharmaceuticals and Medical Devices Agency (PMDA), Kasumigaseki, Chiyoda-ku, Tokyo, Japan
| | - Miho Kasuga
- Pharmaceuticals and Medical Devices Agency (PMDA), Kasumigaseki, Chiyoda-ku, Tokyo, Japan
| | - Joy Van Oudtshoorn
- South African Health Products Regulatory Authority (SAHPRA), Loftus Park, Arcadia, Pretoria, South Africa
| | | | - Wen-Yi Hung
- Taiwan Food and Drug Administration (TFDA), Nangang, Taipei, Taiwan, R.O.C
| | - Li-Feng Hsu
- Center for Drug Evaluation (CDE), Taipei, Taiwan R.O.C
| | | | - Tony Jarman
- Therapeutic Goods Administration (TGA), Woden, Australia
| | - April Braddy
- U.S. Department of Health and Human Services, Food and Drug Administration (USFDA), Center for Drug Evaluation and Research, Office of Generic Drugs, Silver Spring, Maryland, USA
| |
Collapse
|
21
|
Kim N, Tringale KR, Crane C, Tyagi N, Otazo R. MR SIGnature MAtching (MRSIGMA) with retrospective self-evaluation for real-time volumetric motion imaging. Phys Med Biol 2021; 66. [PMID: 34619666 DOI: 10.1088/1361-6560/ac2dd2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 10/07/2021] [Indexed: 11/11/2022]
Abstract
Objective. MR SIGnature MAtching (MRSIGMA) is a real-time volumetric MRI technique to image tumor and organs at risk motion in real-time for radiotherapy applications, where a dictionary of high-resolution 3D motion states and associated motion signatures are computed first during offline training and real-time 3D imaging is performed afterwards using fast signature-only acquisition and signature matching. However, the lack of a reference image with similar spatial resolution and temporal resolution introduces significant challenges forin vivovalidation.Approach. This work proposes a retrospective self-validation for MRSIGMA, where the same data used for real-time imaging are used to create a non-real-time reference for comparison. MRSIGMA with self-validation is tested in patients with liver tumors using quantitative metrics defined on the tumor and nearby organs-at-risk structures. The dice coefficient between contours defined on the real-time MRSIGMA and non-real-time reference was used to assess motion imaging performance.Main Results. Total latency (including signature acquisition and signature matching) was between 250 and 314 ms, which is sufficient for organs affected by respiratory motion. Mean ± standard deviation dice coefficient over time was 0.74 ± 0.03 for patients imaged without contrast agent and 0.87 ± 0.03 for patients imaged with contrast agent, which demonstrated high-performance real-time motion imaging.Signficance. MRSIGMA with self-evaluation provides a means to perform real-time volumetric MRI for organ motion tracking with quantitative performance measures.
Collapse
Affiliation(s)
- Nathanael Kim
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
| | - Kathryn R Tringale
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
| | - Ricardo Otazo
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.,Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
| |
Collapse
|
22
|
Han X, Hong J, Reyngold M, Crane C, Cuaron J, Hajj C, Mann J, Zinovoy M, Greer H, Yorke E, Mageras G, Niethammer M. Deep-learning-based image registration and automatic segmentation of organs-at-risk in cone-beam CT scans from high-dose radiation treatment of pancreatic cancer. Med Phys 2021; 48:3084-3095. [PMID: 33905539 DOI: 10.1002/mp.14906] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 04/02/2021] [Accepted: 04/08/2021] [Indexed: 11/05/2022] Open
Abstract
PURPOSE Accurate deformable registration between computed tomography (CT) and cone-beam CT (CBCT) images of pancreatic cancer patients treated with high biologically effective radiation doses is essential to assess changes in organ-at-risk (OAR) locations and shapes and to compute delivered dose. This study describes the development and evaluation of a deep-learning (DL) registration model to predict OAR segmentations on the CBCT derived from segmentations on the planning CT. METHODS The DL model is trained with CT-CBCT image pairs of the same patient, on which OAR segmentations of the small bowel, stomach, and duodenum have been manually drawn. A transformation map is obtained, which serves to warp the CT image and segmentations. In addition to a regularity loss and an image similarity loss, an OAR segmentation similarity loss is also used during training, which penalizes the mismatch between warped CT segmentations and manually drawn CBCT segmentations. At test time, CBCT segmentations are not required as they are instead obtained from the warped CT segmentations. In an IRB-approved retrospective study, a dataset consisting of 40 patients, each with one planning CT and two CBCT scans, was used in a fivefold cross-validation to train and evaluate the model, using physician-drawn segmentations as reference. Images were preprocessed to remove gas pockets. Network performance was compared to two intensity-based deformable registration algorithms (large deformation diffeomorphic metric mapping [LDDMM] and multimodality free-form [MMFF]) as baseline. Evaluated metrics were Dice similarity coefficient (DSC), change in OAR volume within a volume of interest (enclosing the low-dose PTV plus 1 cm margin) from planning CT to CBCT, and maximum dose to 5 cm3 of the OAR [D(5cc)]. RESULTS Processing time for one CT-CBCT registration with the DL model at test time was less than 5 seconds on a GPU-based system, compared to an average of 30 minutes for LDDMM optimization. For both small bowel and stomach/duodenum, the DL model yielded larger median DSC and smaller interquartile variation than either MMFF (paired t-test P < 10-4 for both type of OARs) or LDDMM (P < 10-3 and P = 0.03 respectively). Root-mean-square deviation (RMSD) of DL-predicted change in small bowel volume relative to reference was 22% less than for MMFF (P = 0.007). RMSD of DL-predicted stomach/duodenum volume change was 28% less than for LDDMM (P = 0.0001). RMSD of DL-predicted D(5cc) in small bowel was 39% less than for MMFF (P = 0.001); in stomach/duodenum, RMSD of DL-predicted D(5cc) was 18% less than for LDDMM (P < 10-3 ). CONCLUSIONS The proposed deep network CT-to-CBCT deformable registration model shows improved segmentation accuracy compared to intensity-based algorithms and achieves an order-of-magnitude reduction in processing time.
Collapse
Affiliation(s)
- Xu Han
- Department of Computer Science, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Jun Hong
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Marsha Reyngold
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - John Cuaron
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Carla Hajj
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Justin Mann
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Melissa Zinovoy
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Hastings Greer
- Department of Computer Science, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Ellen Yorke
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Gig Mageras
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Marc Niethammer
- Department of Computer Science, University of North Carolina, Chapel Hill, NC, 27599, USA
| |
Collapse
|
23
|
Hall WA, Small C, Paulson E, Koay EJ, Crane C, Intven M, Daamen LA, Meijer GJ, Heerkens HD, Bassetti M, Rosenberg SA, Aitken K, Myrehaug S, Dawson LA, Lee P, Gani C, Chuong MD, Parikh PJ, Erickson BA. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Front Oncol 2021; 11:628155. [PMID: 34046339 PMCID: PMC8144850 DOI: 10.3389/fonc.2021.628155] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 03/03/2021] [Indexed: 12/15/2022] Open
Abstract
Introduction Pancreatic adenocarcinoma (PAC) has some of the worst treatment outcomes for any solid tumor. PAC creates substantial difficulty for effective treatment with traditional RT delivery strategies primarily secondary to its location and limited visualization using CT. Several of these challenges are uniquely addressed with MR-guided RT. We sought to summarize and place into context the currently available literature on MR-guided RT specifically for PAC. Methods A literature search was conducted to identify manuscript publications since September 2014 that specifically used MR-guided RT for the treatment of PAC. Clinical outcomes of these series are summarized, discussed, and placed into the context of the existing pancreatic literature. Multiple international experts were involved to optimally contextualize these publications. Results Over 300 manuscripts were reviewed. A total of 6 clinical outcomes publications were identified that have treated patients with PAC using MR guidance. Successes, challenges, and future directions for this technology are evident in these publications. MR-guided RT holds theoretical promise for the treatment of patients with PAC. As with any new technology, immediate or dramatic clinical improvements associated with its use will take time and experience. There remain no prospective trials, currently publications are limited to small retrospective experiences. The current level of evidence for MR guidance in PAC is low and requires significant expansion. Future directions and ongoing studies that are currently open and accruing are identified and reviewed. Conclusions The potential promise of MR-guided RT for PAC is highlighted, the challenges associated with this novel therapeutic intervention are also reviewed. Outcomes are very early, and will require continued and long term follow up. MR-guided RT should not be viewed in the same fashion as a novel chemotherapeutic agent for which dosing, administration, and toxicity has been established in earlier phase studies. Instead, it should be viewed as a novel procedural intervention which must be robustly tested, refined and practiced before definitive conclusions on the potential benefits or detriments can be determined. The future of MR-guided RT for PAC is highly promising and the potential implications on PAC are substantial.
Collapse
Affiliation(s)
- William A Hall
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Christina Small
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Eric Paulson
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Eugene J Koay
- Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | - Martijn Intven
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Lois A Daamen
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Gert J Meijer
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Hanne D Heerkens
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Michael Bassetti
- Department of Radiation Oncology, University of Wisconsin-Madison, Madison, WI, United States
| | - Stephen A Rosenberg
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States
| | - Katharine Aitken
- Department of Radiation Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Sten Myrehaug
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Laura A Dawson
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Percy Lee
- Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Cihan Gani
- Department of Radiation Oncology, Faculty of Medicine, University of Tübingen, Tübingen, Germany
| | | | - Parag J Parikh
- Henry Ford Medical Center, Henry Ford Health System, Detroit, MI, United States
| | - Beth A Erickson
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States
| |
Collapse
|
24
|
Oswald T, Crane C, Hwang C, Craw J, Falla T, Rodan K, Fields K. 138 Environmental stress protection and inflammaging prevention: A novel synergistic antioxidant blend. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Garcia Arieta A, Simon C, Tam A, Mendes Lima Santos G, Freitas Fernandes EA, Rodríguez Martínez Z, Rodrigues C, Park SA, Kim J, Kim K, Kuribayashi R, Myoenzono A, Shimojo K, Walther C, Roost MS, Hung WY, Hsu LF, Crane C, Braddy AC, Van Oudtshoorn J, Gutierrez Triana DA, Guzmán Aurela E, Jones B, Potthast H, Abalos I. A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme. J Pharm Pharm Sci 2021; 24:113-126. [DOI: 10.18433/jpps31491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The requirements to waive in vivo bioequivalence studies for immediate release solid oral dosage forms based on the Biopharmaceutics Classifications System (BCS) are well known, and biowaivers[1] for other types of oral dosage forms based on pre-defined criteria may also be acceptable. Similarly, biowaivers for dosage forms such as injectable products may also be allowed if certain criteria are met. The current paper summarises the biowaiver requirements for oral solutions and suspensions, soft gelatin capsules and injectable products (intravenous injections, subcutaneous and intramuscular injections, emulsions for injection and micellar solutions for injection) among the participants of the Bioequivalence Working Group for Generics (BEWGG) of the International Pharmaceutical Regulators Programme (IPRP). A review of the requirements indicated that there was a trend towards convergence when the dosage form became less complex; however, the most common approach used by each of the jurisdictions was a case-by-case approach given that most jurisdictions do not have well defined guidelines to support all possible scenarios. Even in the simplest case of intravenous solutions, the acceptability of qualitative changes in excipients differ between the IPRP members. Notwithstanding the differences, the dissemination of the information is a first step towards regulatory convergence regarding biowaivers for certain dosage forms and should be useful for pharmaceutical companies currently developing generic medicinal products for IPRP jurisdictions.
Collapse
|
26
|
Montovano M, Zhang M, Oh P, Thor M, Crane C, Yorke E, Wu AJ, Jackson A. Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer. Adv Radiat Oncol 2021; 6:100648. [PMID: 34195487 PMCID: PMC8233466 DOI: 10.1016/j.adro.2021.100648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 11/19/2020] [Accepted: 01/05/2021] [Indexed: 02/07/2023] Open
Abstract
Purpose To determine the incidence and predictors of gastric bleeding after chemoradiation for esophageal or gastroesophageal junction cancer. Methods and Materials We reviewed patients receiving chemoradiation to at least 41.4 Gy for localized esophageal cancer whose fields included the stomach and who did not undergo surgical resection. The primary endpoint was grade ≥3 gastric hemorrhage (GB3+). Comprehensive stomach dose-volume parameters were collected, and stomach dose-volume histograms were generated for analysis. Results A total of 145 patients met our inclusion criteria. Median prescribed dose was 50.4 Gy (range, 41.4-56 Gy). Median stomach Dmax was 53.0 Gy (1.0-62.7 Gy), and median stomach V40, V45, and V50 Gy were 112 cm3 (0-667 cm3), 84 cm3 (0-632 cm3), and 50 cm3 (0-565 cm3), respectively. Two patients (1.4%) developed radiation-induced GB3+. The only dosimetric factor that was significantly different for these patients was a higher stomach Dmax (58.1 and 58.3 Gy) than the cohort median (53 Gy). One of these patients also had cirrhosis, and the other had a history of nonsteroidal anti-inflammatory drug use. Five other patients had GB3+ events associated with documented tumor progression. A Cox proportional hazards model based on stomach Dmax with respect to the development of GB3+ was found to be statistically significant. Time-to-event curves and dose-volume atlases were generated, demonstrating an increased risk of GB3+ only when stomach Dmax was >58 Gy (P < .05). Conclusions We observed a low rate of GB3+ events in patients who received chemoradiation to a median dose of 50.4 Gy to volumes that included a significant portion of the stomach. These results suggest that when prescribing 50.4 Gy for esophageal cancer, there is no need to minimize the irradiated gastric volume or dose for the sake of preventing bleeding complications. Limiting stomach maximum doses to <58 Gy may also avoid bleeding, and particular caution should be taken in patients with other risk factors for bleeding, such as cirrhosis.
Collapse
Affiliation(s)
- Margaret Montovano
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.,Rutgers New Jersey Medical School, Newark, New Jersey
| | - Minsi Zhang
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Patrick Oh
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Maria Thor
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ellen Yorke
- Rutgers New Jersey Medical School, Newark, New Jersey
| | - Abraham J Wu
- Rutgers New Jersey Medical School, Newark, New Jersey
| | | |
Collapse
|
27
|
Ilson D, Moughan J, Safran H, Wigle D, Depetrillo T, Haddock M, Hong T, Leichman L, Rajdev L, Resnick M, Kachnic L, Seaward S, Mamon H, Pardo DD, Anderson C, Shen X, Sharma A, Katz A, Salo J, Leonard K, Crane C. O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.063] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
28
|
Walker L, Kreitinger J, Wageling N, Fields K, Rodan K, Craw J, Falla T, Crane C, Diaz P. 254 AKR1B10 inhibition in keratinocytes as a strategy to improve retinaldehyde efficacy and increase endogenous atRA. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
29
|
Godoy Scripes P, Subashi E, Burleson S, Liang J, Romesser P, Crane C, Mechalakos J, Hunt M, Tyagi N. Impact of varying air cavity on planning dosimetry for rectum patients treated on a 1.5 T hybrid MR-linac system. J Appl Clin Med Phys 2020; 21:144-152. [PMID: 32445292 PMCID: PMC7386179 DOI: 10.1002/acm2.12903] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 04/08/2020] [Accepted: 04/16/2020] [Indexed: 11/20/2022] Open
Abstract
Purpose To investigate the dosimetric impact of magnetic (B) field on varying air cavities in rectum patients treated on the hybrid 1.5 T MR‐linac. Methods Artificial air cavities of varying diameters (0.0, 1.0, 1.5, 2.0, 2.5, 3.0, and 5.0 cm) were created for four rectum patients (two prone and two supine). A total of 56 plans using a 7 MV flattening filter‐free beam were generated with and without B‐field. Reference intensity‐modulated radiation therapy treatment plans without air cavity in the presence and absence of B‐field were generated to a total dose of 45/50 Gy. The reference plans were copied and recalculated for the varying air cavities. D95(PTV45–PTV50), D95(PTV50–aircavity), V50(PTV50–aircavity), Dmax(PTV50–aircavity), and V110%(PTV50–aircavity) were extracted for each patient. Annulus rings of 1‐mm‐diameter step size were generated for one of the air cavity plans (3.0 cm) for all four patients to determine Dmax (%) and V110% (cc) within each annulus. Results In the presence of B‐field, hot spots at the cavity interface start to become visible at ~1 cm air cavity in both supine and prone positioning due to electron return effect (ERE). In the presence of B‐field Dmax and V110% varied from 5523 ± 49 cGy and 0.09 ± 0.16 cc for 0 cm air cavity size to 6050 ± 109 cGy and 11.6 ± 6.7 cc for 5 cm air cavity size. The hot spots were located within 3 mm inside the rectal‐air interface, where Dmax increased from 110.4 ± 0.5% without B‐field to 119.2 ± 0.8 % with B‐field. Conclusions Air cavities inside rectum affects rectum plan dosimetry due ERE. Location and magnitude of hot spots are dependent on the size of the air cavity.
Collapse
Affiliation(s)
- Paola Godoy Scripes
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Ergys Subashi
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Sarah Burleson
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Jiayi Liang
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Paul Romesser
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - James Mechalakos
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Margie Hunt
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Neelam Tyagi
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
30
|
Chuong MD, Kaiser A, Khan F, Parikh P, Ben-Josef E, Crane C, Brunner T, Okumura T, Schreuder N, Bentzen SM, Gutierrez A, Mendez Romero A, Yoon SM, Sharma N, Kim TH, Kishi K, Moeslein F, Hoffe S, Schefter T, Hanish S, Scorsetti M, Apisarnthanarax S. Consensus Report From the Miami Liver Proton Therapy Conference. Front Oncol 2019; 9:457. [PMID: 31214502 PMCID: PMC6557299 DOI: 10.3389/fonc.2019.00457] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 05/14/2019] [Indexed: 12/14/2022] Open
Abstract
An international group of 22 liver cancer experts from 18 institutions met in Miami, Florida to discuss the optimal utilization of proton beam therapy (PBT) for primary and metastatic liver cancer. There was consensus that PBT may be preferred for liver cancer patients expected to have a suboptimal therapeutic ratio from XRT, but that PBT should not be preferred for all patients. Various clinical scenarios demonstrating appropriateness of PBT vs. XRT were reviewed.
Collapse
Affiliation(s)
- Michael D Chuong
- Baptist Hospital of Miami, Miami Cancer Institute, Miami, FL, United States
| | - Adeel Kaiser
- University of Maryland Medical Center, Baltimore, MD, United States
| | - Fazal Khan
- Baptist Hospital of Miami, Miami Cancer Institute, Miami, FL, United States
| | - Parag Parikh
- Henry Ford Health System, Detroit, MI, United States
| | - Edgar Ben-Josef
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | | | - Toshiyuki Okumura
- Department of Radiation Oncology, University of Tsukuba, Tsukuba, Japan
| | - Niek Schreuder
- Provision CARES Proton Therapy, Knoxville, TN, United States
| | - Søren M Bentzen
- University of Maryland Medical Center, Baltimore, MD, United States
| | - Alonso Gutierrez
- Baptist Hospital of Miami, Miami Cancer Institute, Miami, FL, United States
| | - Alejandra Mendez Romero
- Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, Netherlands.,Holland Proton Treatment Center, Rotterdam, Netherlands
| | - Sang Min Yoon
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Navesh Sharma
- Department of Radiation Oncology, Pennsylvania State University, University Park, PA, United States
| | | | | | - Fred Moeslein
- Sarasota Memorial Hospital, Sarasota, FL, United States
| | - Sarah Hoffe
- Moffitt Cancer Center, Tampa, FL, United States
| | - Tracey Schefter
- University of Colorado Anschutz Medical Campus, Aurora, CO, United States
| | - Steven Hanish
- University of Maryland Medical Center, Baltimore, MD, United States
| | - Marta Scorsetti
- Department of Radiation Oncology, Humanitas University, Rozzano, Italy
| | - Smith Apisarnthanarax
- Department of Radiation Oncology, University of Washington, Seattle, WA, United States
| |
Collapse
|
31
|
Dueva-Koganov O, Crane C, Oswald T, Skobowiat C, Bianchini R, Mahon C, Falla T. 860 Evaluation of topical dermatologics containing L-ascorbic acid and its esters on Melanoderm™. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Skobowiat C, Dueva-Koganov O, Crane C, Mahon C, Bianchini R, Rodan K, Fields K, Falla T. 859 Evaluation of Kojic Acid and Hydroquinone on Melanoderm™ skin model as controls in screening architecture for skin lightening actives and formulas. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37:1015-1027. [PMID: 30856044 DOI: 10.1200/jco.18.02178] [Citation(s) in RCA: 252] [Impact Index Per Article: 50.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Collapse
Affiliation(s)
| | | | | | | | | | | | - Anthony El-Khoueiry
- 7 University of Southern California Kenneth Norris Cancer Center, Los Angeles, CA
| | - Mary Feng
- 8 University of California, San Francisco, CA
| | - Matthew H G Katz
- 9 The University of Texas MD Anderson Cancer Center, Houston, TX
| | - John Primrose
- 10 University of Southampton, Southampton, United Kingdom
| | - Heloisa P Soares
- 11 University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
| | - Juan Valle
- 12 University of Manchester Institute of Cancer Sciences, Manchester, United Kingdom
| | | |
Collapse
|
34
|
Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol 2019; 5:e185896. [PMID: 30629084 DOI: 10.1001/jamaoncol.2018.5896] [Citation(s) in RCA: 300] [Impact Index Per Article: 60.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Importance The watch-and-wait (WW) strategy aims to spare patients with rectal cancer unnecessary resection. Objective To analyze the outcomes of WW among patients with rectal cancer who had a clinical complete response to neoadjuvant therapy. Design, Setting, and Participants This retrospective case series analysis conducted at a comprehensive cancer center in New York included patients who received a diagnosis of rectal adenocarcinoma between January 1, 2006, and January 31, 2015. The median follow-up was 43 months. Data analyses were conducted from June 1, 2016, to October 1, 2018. Exposures Patients had a clinical complete response after completing neoadjuvant therapy and agreed to a WW strategy of active surveillance and possible salvage surgery (n = 113), or patients underwent total mesorectal excision and were found to have a pathologic complete response (pCR) at resection (n = 136). Main Outcomes and Measures Kaplan-Meier estimates were used for analyses of local regrowth and 5-year rates of overall survival, disease-free survival, and disease-specific survival. Results Compared with the 136 patients in the pCR group, the 113 patients in the WW group were older (median [range], 67.2 [32.1-90.9] vs 57.3 [25.0-87.9] years, P < .001) with cancers closer to the anal verge (median [range] height from anal verge, 5.5 [0.0-15.0] vs 7.0 [0.0-13.0] cm). All 22 local regrowths in the WW group were detected on routine surveillance and treated by salvage surgery (20 total mesorectal excisions plus 2 transanal excisions). Pelvic control after salvage surgery was maintained in 20 of 22 patients (91%). No pelvic recurrences occurred in the pCR group. Rectal preservation was achieved in 93 of 113 patients (82%) in the WW group (91 patients with no local regrowths plus 2 patients with local regrowths salvaged with transanal excision). At 5 years, overall survival was 73% (95% CI, 60%-89%) in the WW group and 94% (95% CI, 90%-99%) in the pCR group; disease-free survival was 75% (95% CI, 62%-90%) in the WW group and 92% (95% CI, 87%-98%) in the pCR group; and disease-specific survival was 90% (95% CI, 81%-99%) in the WW group and 98% (95% CI, 95%-100%) in the pCR group. A higher rate of distant metastasis was observed among patients in the WW group who had local regrowth vs those who did not have local regrowth (36% vs 1%, P < .001). Conclusions and Relevance A WW strategy for select rectal cancer patients who had a clinical complete response after neoadjuvant therapy resulted in excellent rectal preservation and pelvic tumor control; however, in the WW group, worse survival was noted along with a higher incidence of distant progression in patients with local regrowth vs those without local regrowth.
Collapse
Affiliation(s)
- J Joshua Smith
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Paul Strombom
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Oliver S Chow
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Campbell S Roxburgh
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.,Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Patricio Lynn
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Anne Eaton
- Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Maria Widmar
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Karuna Ganesh
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Rona Yaeger
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Andrea Cercek
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Martin R Weiser
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Garrett M Nash
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jose G Guillem
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Larissa K F Temple
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sree B Chalasani
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - James L Fuqua
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Iva Petkovska
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Abraham J Wu
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marsha Reyngold
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Efsevia Vakiani
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jinru Shia
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Neil H Segal
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - James D Smith
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christopher Crane
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marc J Gollub
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Mithat Gonen
- Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Leonard B Saltz
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Julio Garcia-Aguilar
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Philip B Paty
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
35
|
Frazee R, Regner J, Truitt MS, Agrawal V, Swope M, Burlew CC, Dissanaike S, Vangipurum D, Bruns B, O'Meara L, Stivers J, Kwok A, Grover BT, Kothari SN, Cibari C, Dunn J, McIntyre RC, Wright F, Scherer EP, Crane C, Schroeppel TJ, Callaghan E, Gordy S, Todd R. The southwestern surgical congress multi-center trial on suspected common duct stones. Am J Surg 2019; 217:1006-1009. [PMID: 30654919 DOI: 10.1016/j.amjsurg.2018.12.062] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Revised: 10/15/2018] [Accepted: 12/29/2018] [Indexed: 11/18/2022]
Abstract
BACKGROUND Choledocholithiasis is present in up to 15% of cholecystectomy patients. Treatment can be surgical, endoscopic, or via interventional radiology. We hypothesized significant heterogeneity between hospitals exists in the approach to suspected common duct stones. METHODS A retrospective review of patients that had a preoperative MRCP, endoscopic ultrasound, endoscopic retrograde cholangiopancreatogram (ERCP), or intra-operative cholangiogram was performed. Comparisons were by Wilcoxon-Mann-Whitney tests with significance of p < 0.05 for paired variables and p < 0.017 for multiple comparisons. RESULTS Twelve participating institutions identified 1263 patients (409 men and 854 women) with a median age of 49 years (IQR: 31-94). Liver function tests (LFT's) were elevated in 939 patients (75%), median bilirubin level 1.75 mg/dl (IQ: 0.8-3.7 mg/dl) and median common duct size 7 mm (IQR 5-10 mm). The most common initial procedure was cholecystectomy with IOC at seven institutions, endoscopy at four and MRCP at one. CONCLUSION Significant variation exists within the surgical community regarding suspected common duct stones. These results underscore the need for a protocol for common duct stones to minimize multiple, redundant interventions.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sharmila Dissanaike
- Department of Surgery, Texas Tech University Health, Sciences Center Lubbock TX, USA
| | - Divya Vangipurum
- Department of Surgery, Texas Tech University Health, Sciences Center Lubbock TX, USA
| | | | | | - John Stivers
- Department of Surgery, University of California San Francisco-Fresno, USA
| | - Amy Kwok
- Department of Surgery, University of California San Francisco-Fresno, USA
| | | | | | | | | | | | - Frank Wright
- University of Colorado Hospital, Aurora, Colorado, USA
| | | | | | - Thomas J Schroeppel
- University of Colorado Health - Memorial Hospital, Colorado Springs, CO, USA
| | - Emma Callaghan
- University of Colorado Health - Memorial Hospital, Colorado Springs, CO, USA
| | | | | |
Collapse
|
36
|
Garcia Arieta A, Simon C, Lima Santos GM, Calderón Lojero IO, Rodríguez Martínez Z, Rodrigues C, Park SA, Kim JM, Kuribayashi R, Okada Y, Nolting A, Pfäffli C, Hung WY, Crane C, Braddy AC, Van Oudtshoorn J, Gutierrez Triana D, Clarke M. A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme. J Pharm Pharm Sci 2019; 22:28-36. [DOI: 10.18433/jpps30215] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The acceptance of foreign comparator products is the most limiting factor for the development and regulatory assessment of generic medicines marketed globally. Bioequivalence studies have to be repeated with the local comparator products of each jurisdiction because it is unknown if the comparators of the different countries are the same product, with the consequent duplication of efforts by regulators and industry alike. The regulatory requirements on the acceptability of foreign comparator products of oral dosage forms differ between countries participating in the Bioequivalence Working Group for Generics of the International Pharmaceutical Regulators Programme. Brazil, Colombia, the European Union member States, Japan, Mexico, South Korea and the United States only accept bioequivalence studies with their local comparator. In contrast, Australia, Canada, New Zealand, Singapore, South Africa, Switzerland and Taiwan accept studies with foreign comparators under certain conditions. Canada limits its use to highly soluble drugs with a wide therapeutic range in immediate release products. Australia requires a comparison of the quantitative composition. In contrast, there are fewer restrictions on the acceptance of foreign comparators in New Zealand, Singapore, South Africa, Switzerland and Taiwan. For the WHO Prequalification of Medicines and for developing generics of the essential medicines the WHO lists comparators from different countries. In conclusion, there is currently no consensus amongst regulators on the acceptability of foreign comparator products.
Collapse
|
37
|
Crane C, Santos GML, Fernandes EAF, Simon C, Tam A, Triana DG, Potthast H, Kuribayashi R, Okada Y, Myoenzono A, Calderon IO, Rodriguez Z, Jones B, Park SA, Eum SY, Rodrigues C, Van Oudsthoorn J, Nolting A, Walther C, Roost MS, Hung WY, Braddy AC, Garcia-Arieta A. The Requirements for Additional Strength Biowaivers for Immediate Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities. J Pharm Pharm Sci 2019; 22:486-500. [PMID: 33760728 DOI: 10.18433/jpps30724] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
In relation to the registration of generic products, waivers of in vivo bioequivalence studies (biowaivers) are considered in three main cases: certain dosage forms for which bioequivalence is self-evident (e.g. intravenous solutions), biowaivers based on the Biopharmaceutics Classification System and biowaivers for additional strengths with respect to the strength for which in vivo bioequivalence has been shown. The objective of this article is to describe the differences and commonalities in biowaivers for additional strengths of immediate release solid oral dosage forms between the participating members of the International Pharmaceutical Regulators Program (IPRP). The requirements are based on five main aspects; the pharmacokinetics of the drug substance, the manufacturing process, the qualitative and quantitative composition of the different strengths, and the comparative dissolution profiles. For the pharmacokinetic aspects, many regulators/agencies have the same requirements. All strengths must be manufactured with the same process, although a few regulators/agencies accept small differences. In relation to the formulation aspects, the data required breaks down into three major approaches based initially on one of those of the EU, the USA or Japan, but there are some differences in these three major approaches with some country specific interpretations. Most regulators/agencies also have the same requirements for the dissolution data, though there are some notable exceptions.
Collapse
|
38
|
Gjelsvik B, Kappelmann N, von Soest T, Hinze V, Baer R, Hawton K, Crane C. Thought-Action Fusion in Individuals with a History of Recurrent Depression and Suicidal Depression: Findings from a Community Sample. Cognit Ther Res 2018; 42:782-793. [PMID: 30416229 PMCID: PMC6208973 DOI: 10.1007/s10608-018-9924-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Although suicidal ideation is one of the most consistent symptoms across recurrent episodes of depression, the mechanisms underpinning its maintenance are poorly understood. In order to develop effective treatments for suicidally depressed patients, understanding what maintains suicidal distress is critical. We hypothesised that Thought–Action Fusion (TAF), i.e., to assume that having a thought has real world consequences, originally described in Obsessive–Compulsive Disorder, might be a bias in recurrently suicidally depressed people. To assess this, we revised the original TAF scale, and assessed TAF in three samples: healthy controls, recurrently depressed individuals with no history of suicidality (D-NS) and individuals with a history of recurrent suicidal depression (D-S). Exploratory and confirmatory factor analyses indicated a three-factor solution of TAF: (1) TAF for uncontrollable events, (2) self-suicidal TAF for suicidal acts related to oneself, and (3) TAF for positive controllable events. Compared to healthy controls, the D-NS group reported significantly higher total TAF, TAF uncontrollable, and TAF self-suicidal subscales, whilst positive controllable TAF was lower compared to healthy controls. Both D-S and D-NS samples reported higher TAF for suicidal thought compared to healthy controls, i.e., believing that having suicidal thoughts means they will act on them, however in the context of low mood this became more pronounced for the D-S group. These findings suggest that targeting TAF both in suicidal and non-suicidal depression has merit.
Collapse
Affiliation(s)
- B Gjelsvik
- 1Department of Psychiatry, University of Oxford, Oxford, UK.,2Department of Psychology, University of Oslo, Oslo, Norway.,3Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX37JX UK
| | - N Kappelmann
- 1Department of Psychiatry, University of Oxford, Oxford, UK
| | - T von Soest
- 2Department of Psychology, University of Oslo, Oslo, Norway
| | - V Hinze
- 1Department of Psychiatry, University of Oxford, Oxford, UK
| | - R Baer
- 2Department of Psychology, University of Oslo, Oslo, Norway.,4University of Kentucky, Lexington, USA
| | - K Hawton
- 1Department of Psychiatry, University of Oxford, Oxford, UK
| | - C Crane
- 1Department of Psychiatry, University of Oxford, Oxford, UK
| |
Collapse
|
39
|
Van Oudtshoorn JE, García-Arieta A, Santos GML, Crane C, Rodrigues C, Simon C, Kim JM, Park SA, Okada Y, Kuribayashi R, Pfäffli C, Nolting A, Lojero10 IOC, Martínez ZR, Hung WY, Braddy AC, Leal NA, Triana DG, Clarke M, Bachmann P. A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme. J Pharm Pharm Sci 2018; 21:27-37. [DOI: 10.18433/j3x93k] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Purpose: The Biopharmaceutics Classification System (BCS) based biowaiver is a scientific model which enables the substitution of in vivo bioequivalence studies with in vitro data as evidence of therapeutic equivalence subject to certain conditions. Despite being based on the same principles, BCS-based biowaivers are interpreted and regulated differently among international regulatory agencies. In this survey, the Bioequivalence Working Group (BEWG) of the International Generic Drug Regulators Programme (IGDRP) compared the criteria for BCS-based biowaivers applied by the participating regulators and organisations. Methods: Differences and similarities regarding solubility, permeability, dissolution, excipients and fixed-dose combination products, were identified and compared in a detailed survey of each participant’s criteria for BCS-based biowaivers. These criteria were determined based upon the participants’ respective regulatory guidance documents, policies and practices. Results: This review has, with the exception of two participants who do not accept BCS-based biowaivers, revealed that most IGDRP participants interpret the BCS principles and conditions similarly but notable differences exist in the application of these principles. Conclusion: Although many similarities exist, this review identifies several opportunities for greater convergence of regulatory requirements amongst the surveyed jurisdictions. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page
Collapse
|
40
|
Crous P, Wingfield M, Burgess T, Hardy G, Barber P, Alvarado P, Barnes C, Buchanan P, Heykoop M, Moreno G, Thangavel R, van der Spuy S, Barili A, Barrett S, Cacciola S, Cano-Lira J, Crane C, Decock C, Gibertoni T, Guarro J, Guevara-Suarez M, Hubka V, Kolařík M, Lira C, Ordoñez M, Padamsee M, Ryvarden L, Soares A, Stchigel A, Sutton D, Vizzini A, Weir B, Acharya K, Aloi F, Baseia I, Blanchette R, Bordallo J, Bratek Z, Butler T, Cano-Canals J, Carlavilla J, Chander J, Cheewangkoon R, Cruz R, da Silva M, Dutta A, Ercole E, Escobio V, Esteve-Raventós F, Flores J, Gené J, Góis J, Haines L, Held B, Jung MH, Hosaka K, Jung T, Jurjević Ž, Kautman V, Kautmanova I, Kiyashko A, Kozanek M, Kubátová A, Lafourcade M, La Spada F, Latha K, Madrid H, Malysheva E, Manimohan P, Manjón J, Martín M, Mata M, Merényi Z, Morte A, Nagy I, Normand AC, Paloi S, Pattison N, Pawłowska J, Pereira O, Petterson M, Picillo B, Raj K, Roberts A, Rodríguez A, Rodríguez-Campo F, Romański M, Ruszkiewicz-Michalska M, Scanu B, Schena L, Semelbauer M, Sharma R, Shouche Y, Silva V, Staniaszek-Kik M, Stielow J, Tapia C, Taylor P, Toome-Heller M, Vabeikhokhei J, van Diepeningen A, Van Hoa N, M. VT, Wiederhold N, Wrzosek M, Zothanzama J, Groenewald J. Fungal Planet description sheets: 558-624. Persoonia 2017; 38:240-384. [PMID: 29151634 PMCID: PMC5645186 DOI: 10.3767/003158517x698941] [Citation(s) in RCA: 90] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Accepted: 05/01/2017] [Indexed: 01/20/2023]
Abstract
Novel species of fungi described in this study include those from various countries as follows: Australia: Banksiophoma australiensis (incl. Banksiophoma gen. nov.) on Banksia coccinea, Davidiellomycesaustraliensis (incl. Davidiellomyces gen. nov.) on Cyperaceae, Didymocyrtis banksiae on Banksia sessilis var. cygnorum, Disculoides calophyllae on Corymbia calophylla, Harknessia banksiae on Banksia sessilis, Harknessia banksiae-repens on Banksia repens, Harknessia banksiigena on Banksia sessilis var. cygnorum, Harknessia communis on Podocarpus sp., Harknessia platyphyllae on Eucalyptus platyphylla, Myrtacremonium eucalypti (incl. Myrtacremonium gen. nov.) on Eucalyptus globulus, Myrtapenidiella balenae on Eucalyptus sp., Myrtapenidiella eucalyptigena on Eucalyptus sp., Myrtapenidiella pleurocarpae on Eucalyptuspleurocarpa, Paraconiothyrium hakeae on Hakea sp., Paraphaeosphaeria xanthorrhoeae on Xanthorrhoea sp., Parateratosphaeria stirlingiae on Stirlingia sp., Perthomyces podocarpi (incl. Perthomyces gen. nov.) on Podocarpus sp., Readeriella ellipsoidea on Eucalyptus sp., Rosellinia australiensis on Banksia grandis, Tiarosporella corymbiae on Corymbia calophylla, Verrucoconiothyriumeucalyptigenum on Eucalyptus sp., Zasmidium commune on Xanthorrhoea sp., and Zasmidium podocarpi on Podocarpus sp. Brazil: Cyathus aurantogriseocarpus on decaying wood, Perenniporia brasiliensis on decayed wood, Perenniporia paraguyanensis on decayed wood, and Pseudocercospora leandrae-fragilis on Leandrafragilis.Chile: Phialocephala cladophialophoroides on human toe nail. Costa Rica: Psathyrella striatoannulata from soil. Czech Republic: Myotisia cremea (incl. Myotisia gen. nov.) on bat droppings. Ecuador: Humidicutis dictiocephala from soil, Hygrocybe macrosiparia from soil, Hygrocybe sangayensis from soil, and Polycephalomyces onorei on stem of Etlingera sp. France: Westerdykella centenaria from soil. Hungary: Tuber magentipunctatum from soil. India: Ganoderma mizoramense on decaying wood, Hodophilus indicus from soil, Keratinophyton turgidum in soil, and Russula arunii on Pterigota alata.Italy: Rhodocybe matesina from soil. Malaysia: Apoharknessia eucalyptorum, Harknessia malayensis, Harknessia pellitae, and Peyronellaea eucalypti on Eucalyptus pellita, Lectera capsici on Capsicum annuum, and Wallrothiella gmelinae on Gmelina arborea.Morocco: Neocordana musigena on Musa sp. New Zealand: Candida rongomai-pounamu on agaric mushroom surface, Candida vespimorsuum on cup fungus surface, Cylindrocladiella vitis on Vitis vinifera, Foliocryphia eucalyptorum on Eucalyptus sp., Ramularia vacciniicola on Vaccinium sp., and Rhodotorula ngohengohe on bird feather surface. Poland: Tolypocladium fumosum on a caterpillar case of unidentified Lepidoptera.Russia: Pholiotina longistipitata among moss. Spain: Coprinopsis pseudomarcescibilis from soil, Eremiomyces innocentii from soil, Gyroporus pseudocyanescens in humus, Inocybe parvicystis in humus, and Penicillium parvofructum from soil. Unknown origin: Paraphoma rhaphiolepidis on Rhaphiolepsis indica.USA: Acidiella americana from wall of a cooling tower, Neodactylaria obpyriformis (incl. Neodactylaria gen. nov.) from human bronchoalveolar lavage, and Saksenaea loutrophoriformis from human eye. Vietnam: Phytophthora mekongensis from Citrus grandis, and Phytophthora prodigiosa from Citrus grandis. Morphological and culture characteristics along with DNA barcodes are provided.
Collapse
Affiliation(s)
- P.W. Crous
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| | - M.J. Wingfield
- Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria 0002, South Africa
| | - T.I. Burgess
- Centre for Phytophthora Science and Management, Murdoch University, 90 South Street, Murdoch, WA 6150, Australia
| | - G.E.St.J. Hardy
- Centre for Phytophthora Science and Management, Murdoch University, 90 South Street, Murdoch, WA 6150, Australia
| | - P.A. Barber
- ArborCarbon, P.O. Box 1065, Willagee Central, WA 6156, Australia; 1 City Farm Place, East Perth, Western Australia, 6004 Australia
| | - P. Alvarado
- ALVALAB, C/ La Rochela nº 47, E-39012 Santander, Spain
| | - C.W. Barnes
- Instituto Nacional de Investigaciones Agropecuarias, Estación Experimental Santa Catalina, Panamericana Sur Km1, Sector Cutuglahua, Pichincha, Ecuador
| | - P.K. Buchanan
- Landcare Research, Private Bag 92170, Auckland 1142, New Zealand
| | - M. Heykoop
- Departamento de Ciencias de la Vida (Área de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - G. Moreno
- Departamento de Ciencias de la Vida (Área de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - R. Thangavel
- Plant Health and Environment Laboratory, Ministry for Primary Industries, P.O. Box 2095, Auckland 1140, New Zealand
| | - S. van der Spuy
- Macleans College, 2 Macleans Rd, Bucklands Beach, Auckland 2014, New Zealand
| | - A. Barili
- Escuela de Ciencias Biológicas, Pontificia Universidad Católica del Ecuador, Av. 12 de octubre 1076 y Roca, Quito, Ecuador
| | - S. Barrett
- Department of Parks and Wildlife Albany District, 120 Albany Highway, Albany, WA 6330, Australia
| | - S.O. Cacciola
- Department of Agriculture, Food and Environment (Di3A), University of Catania, Via Santa Sofia 100, 95123 Catania, Italy
| | - J.F. Cano-Lira
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - C. Crane
- Department of Parks and Wildlife, Vegetation Health Service, Locked Bag 104, Bentley Delivery Centre, Bentley, WA 6983, Australia
| | - C. Decock
- Mycothèque de l’Université catholique de Louvain (MUCL, BCCMTM), Earth and Life Institute – Microbiology (ELIM), Université catholique de Louvain, Croix du Sud 2 bte L7.05.06, B-1348, Louvain-la-Neuve, Belgium
| | - T.B. Gibertoni
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - J. Guarro
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - M. Guevara-Suarez
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - V. Hubka
- Department of Botany, Faculty of Science, Charles University, Benátská 2, 128 01 Prague 2, Czech Republic
| | - M. Kolařík
- Laboratory of Fungal Genetics and Metabolism, Institute of Microbiology of the CAS, v.v.i, Vídeňská 1083, 142 20 Prague 4, Czech Republic
| | - C.R.S. Lira
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - M.E. Ordoñez
- Escuela de Ciencias Biológicas, Pontificia Universidad Católica del Ecuador, Av. 12 de octubre 1076 y Roca, Quito, Ecuador
| | - M. Padamsee
- Landcare Research, Private Bag 92170, Auckland 1142, New Zealand
| | - L. Ryvarden
- University of Oslo, Institute of Biological Sciences, P.O. Box 1066, Blindern, N-0316, Oslo, Norway
| | - A.M. Soares
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - A.M. Stchigel
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - D.A. Sutton
- Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA
| | - A. Vizzini
- Department of Life Sciences and Systems Biology, University of Torino, Viale P.A. Mattioli 25, I-10125 Torino, Italy; Institute for Sustainable Plant Protection (IPSP)-CNR, Viale P.A. Mattioli 25, I-10125 Torino, Italy
| | - B.S. Weir
- Landcare Research, Private Bag 92170, Auckland 1142, New Zealand
| | - K. Acharya
- Molecular and Applied Mycology and Plant Pathology Laboratory, Department of Botany, University of Calcutta, 35, Ballygunge Circular Road, Kolkata-700019, West Bengal, India
| | - F. Aloi
- Department of Agriculture, Food and Environment (Di3A), University of Catania, Via Santa Sofia 100, 95123 Catania, Italy
| | - I.G. Baseia
- Departamento de Botânica e Zoologia, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
| | - R.A. Blanchette
- University of Minnesota, 495 Borlaug Hall, 1991 Upper Buford Circle, St. Paul, MN 55108, USA
| | - J.J. Bordallo
- Departamento de Biología Vegetal (Botánica), Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain
| | - Z. Bratek
- Department of Plant Physiology and Molecular Plant Biology, Eötvös Loránd University, Pázmány Péter lane 1/C, Budapest H-1117, Hungary
| | - T. Butler
- Te Kura Kaupapa Māori o Kaikohe, 20 Hongi Street, Kaikohe 0405, New Zealand
| | - J. Cano-Canals
- Te Kura Kaupapa Māori o Kaikohe, 20 Hongi Street, Kaikohe 0405, New Zealand
| | - J.R. Carlavilla
- Departamento de Ciencias de la Vida (Área de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - J. Chander
- Department of Microbiology, Government Medical College Hospital, 32B, Sector 32, Chandigarh, 160030, India
| | - R. Cheewangkoon
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - R.H.S.F. Cruz
- Programa de Pós-graduação em Sistemática e Evolução, Dept. Botânica e Zoologia, Centro de Biociências, Universidade Federal do Rio Grande do Norte, Natal, 59078-970, Brazil
| | - M. da Silva
- Universidade Federal de Viçosa, Minas Gerais, Brazil
| | - A.K. Dutta
- Molecular and Applied Mycology and Plant Pathology Laboratory, Department of Botany, University of Calcutta, 35, Ballygunge Circular Road, Kolkata-700019, West Bengal, India
| | - E. Ercole
- Department of Life Sciences and Systems Biology, University of Turin, I-10125 Turin, Italy
| | - V. Escobio
- Sociedad Micológica de Gran Canaria, Apartado 609, 35080 Las Palmas de Gran Canaria, Spain
| | - F. Esteve-Raventós
- Departamento de Ciencias de la Vida (Área de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - J.A. Flores
- Escuela de Ciencias Biológicas, Pontificia Universidad Católica del Ecuador, Av. 12 de octubre 1076 y Roca, Quito, Ecuador
| | - J. Gené
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - J.S. Góis
- Departamento de Botânica e Zoologia, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
| | - L. Haines
- Te Kura Kaupapa Māori o Kaikohe, 20 Hongi Street, Kaikohe 0405, New Zealand
| | - B.W. Held
- University of Minnesota, 495 Borlaug Hall, 1991 Upper Buford Circle, St. Paul, MN 55108, USA
| | - M. Horta Jung
- Phytophthora Research Center, Mendel University, Zemedelska 1, 613 00 Brno, Czech Republic; Phytophthora Research and Consultancy, Am Rain 9, 83131 Nußdorf, Germany
| | - K. Hosaka
- Department of Botany, National Museum of Nature and Science-TNS, 4-1-1 Amakubo, Tsukuba, Ibaraki, 305-0005, Japan
| | - T. Jung
- Phytophthora Research Center, Mendel University, Zemedelska 1, 613 00 Brno, Czech Republic; Phytophthora Research and Consultancy, Am Rain 9, 83131 Nußdorf, Germany
| | - Ž. Jurjević
- EMSL Analytical, Inc., 200 Route 130 North, Cinnaminson, NJ 08077, USA
| | | | - I. Kautmanova
- Slovak National Museum-Natural History Museum, Vajanskeho nab. 2, P.O. Box 13, 81006 Bratislava, Slovakia
| | - A.A. Kiyashko
- Komarov Botanical Institute of the Russian Academy of Sciences, Saint Petersburg, Russia
| | - M. Kozanek
- Scientica, Ltd., Hybesova 33, 83106 Bratislava, Slovakia
| | - A. Kubátová
- Department of Botany, Faculty of Science, Charles University, Benátská 2, 128 01 Prague 2, Czech Republic
| | - M. Lafourcade
- Laboratorio Clínico, Clínica Santa María, Santiago, Chile
| | - F. La Spada
- Department of Agriculture, Food and Environment (Di3A), University of Catania, Via Santa Sofia 100, 95123 Catania, Italy
| | - K.P.D. Latha
- Department of Botany, University of Calicut, Kerala, 673 635, India
| | - H. Madrid
- Centro de Genómica y Bioinformática, Facultad de Ciencias, Universidad Mayor de Chile, Camino La Pirámide 5750, Huechuraba, Santiago, Chile
| | - E.F. Malysheva
- Komarov Botanical Institute of the Russian Academy of Sciences, Saint Petersburg, Russia
| | - P. Manimohan
- Department of Botany, University of Calicut, Kerala, 673 635, India
| | - J.L. Manjón
- Departamento de Ciencias de la Vida (Área de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - M.P. Martín
- Departamento de Micología, Real Jardín Botánico-CSIC, Plaza de Murillo 2, 28014 Madrid, Spain
| | - M. Mata
- Escuela de Biología, Universidad de Costa Rica, Sede Central, San Pedro de Montes Oca. San José, Costa Rica
| | - Z. Merényi
- Department of Plant Physiology and Molecular Plant Biology, Eötvös Loránd University, Pázmány Péter lane 1/C, Budapest H-1117, Hungary
| | - A. Morte
- Departamento de Biología Vegetal (Botánica), Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain
| | - I. Nagy
- Department of Plant Physiology and Molecular Plant Biology, Eötvös Loránd University, Pázmány Péter lane 1/C, Budapest H-1117, Hungary
| | - A.-C. Normand
- Département de Parasitologie/Mycologie La Timone, Marseille, France
| | - S. Paloi
- Molecular and Applied Mycology and Plant Pathology Laboratory, Department of Botany, University of Calcutta, 35, Ballygunge Circular Road, Kolkata-700019, West Bengal, India
| | - N. Pattison
- Rongomai School, 20 Rongomai Rd, Otara, Auckland 2023, New Zealand
| | - J. Pawłowska
- Department of Molecular Phylogenetics and Evolution, University of Warsaw, Żwirki and Wigury 101, PL-02-089 Warsaw, Poland
| | - O.L. Pereira
- Universidade Federal de Viçosa, Minas Gerais, Brazil
| | - M.E. Petterson
- Landcare Research, Private Bag 92170, Auckland 1142, New Zealand
| | - B. Picillo
- Via Roma 139, I-81017 Sant’ Angelo d’ Alife (CE), Italy
| | - K.N.A. Raj
- Department of Botany, University of Calicut, Kerala, 673 635, India
| | - A. Roberts
- Karamu High School, Windsor Ave, Parkvale, Hastings 4122, New Zealand
| | - A. Rodríguez
- Departamento de Biología Vegetal (Botánica), Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain
| | | | - M. Romański
- Wigry National Park, Krzywe 82, PL-16-402 Suwałki, Poland
| | | | - B. Scanu
- Dipartimento di Agraria, University of Sassari, Viale Italia 39, 07100 Sassari, Italy
| | - L. Schena
- Dipartimento di Agraria, Mediterranean University of Reggio Calabria, Feo di Vito, 89122 Reggio Calabria, Italy
| | - M. Semelbauer
- Institute of Zoology, Slovak Academy of Sciences, Dubravska cesta 9, 84506 Bratislava, Slovakia
| | - R. Sharma
- National Centre for Microbial Resource, National Centre for Cell Science, NCCS Complex SP Pune University Campus, Ganeshkhind, Pune 411007, India
| | - Y.S. Shouche
- National Centre for Microbial Resource, National Centre for Cell Science, NCCS Complex SP Pune University Campus, Ganeshkhind, Pune 411007, India
| | - V. Silva
- Escuela de Tecnología Médica, Facultad de Ciencias, Universidad Mayor de Chile, Santiago, Chile
| | - M. Staniaszek-Kik
- Department of Geobotany and Plant Ecology, University of Łódź, Banacha 12/16, PL-90-237 Łódź, Poland
| | - J.B. Stielow
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| | - C. Tapia
- Laboratorio de Micología Médica, Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - P.W.J. Taylor
- Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Australia
| | - M. Toome-Heller
- Plant Health and Environment Laboratory, Ministry for Primary Industries, P.O. Box 2095, Auckland 1140, New Zealand
| | | | - A.D. van Diepeningen
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| | - N. Van Hoa
- Southern Horticultural Research Institute, My Tho, Tien Giang, Vietnam
| | - Van Tri M.
- Southern Horticultural Research Institute, My Tho, Tien Giang, Vietnam
| | - N.P. Wiederhold
- Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA
| | - M. Wrzosek
- Department of Molecular Phylogenetics and Evolution, University of Warsaw, Żwirki and Wigury 101, PL-02-089 Warsaw, Poland
| | | | - J.Z. Groenewald
- Westerdijk Fungal Biodiversity Institute, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| |
Collapse
|
41
|
Moningi S, Amer A, Colbert L, Lee Y, Wolff R, Varadhachary G, Das P, Herman JM, Taniguchi C, Fleming JB, Katz MH, Crane C, Le O, Bhosale P, Tamm E, Koay EJ. (S022) Can Imaging-Based Biomarkers of Pancreatic Cancer be Used to Select Patients for Dose-Escalated Radiotherapy? Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.02.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Taunk NK, Cohen G, Taggar AS, Damato AL, Crane C, Cuaron J, Nash GM, Smith JJ, Aguilar JG, Wu AJ. Preliminary Clinical Experience from a Phase I Feasibility Study of a Novel Permanent Unidirectional Intraoperative Brachytherapy Device. Brachytherapy 2017. [DOI: 10.1016/j.brachy.2017.04.076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Episcopia K, Cohen GN, Crane C, Taggar AS, Wu AJ, Damato AL. Commissioning and Clinical Use of the CivaSheet, a Novel Shielded Pd103 Array. Brachytherapy 2017. [DOI: 10.1016/j.brachy.2017.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Crous P, Wingfield M, Burgess T, Hardy G, Crane C, Barrett S, Cano-Lira J, Le Roux J, Thangavel R, Guarro J, Stchigel A, Martín M, Alfredo D, Barber P, Barreto R, Baseia I, Cano-Canals J, Cheewangkoon R, Ferreira R, Gené J, Lechat C, Moreno G, Roets F, Shivas R, Sousa J, Tan Y, Wiederhold N, Abell S, Accioly T, Albizu J, Alves J, Antoniolli Z, Aplin N, Araújo J, Arzanlou M, Bezerra J, Bouchara JP, Carlavilla J, Castillo A, Castroagudín V, Ceresini P, Claridge G, Coelho G, Coimbra V, Costa L, da Cunha K, da Silva S, Daniel R, de Beer Z, Dueñas M, Edwards J, Enwistle P, Fiuza P, Fournier J, García D, Gibertoni T, Giraud S, Guevara-Suarez M, Gusmão L, Haituk S, Heykoop M, Hirooka Y, Hofmann T, Houbraken J, Hughes D, Kautmanová I, Koppel O, Koukol O, Larsson E, Latha K, Lee D, Lisboa D, Lisboa W, López-Villalba Á, Maciel J, Manimohan P, Manjón J, Marincowitz S, Marney T, Meijer M, Miller A, Olariaga I, Paiva L, Piepenbring M, Poveda-Molero J, Raj K, Raja H, Rougeron A, Salcedo I, Samadi R, Santos T, Scarlett K, Seifert K, Shuttleworth L, Silva G, Silva M, Siqueira J, Souza-Motta C, Stephenson S, Sutton D, Tamakeaw N, Telleria M, Valenzuela-Lopez N, Viljoen A, Visagie C, Vizzini A, Wartchow F, Wingfield B, Yurchenko E, Zamora J, Groenewald J. Fungal Planet description sheets: 469-557. Persoonia 2016; 37:218-403. [PMID: 28232766 PMCID: PMC5315290 DOI: 10.3767/003158516x694499] [Citation(s) in RCA: 151] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Accepted: 11/12/2016] [Indexed: 01/18/2023]
Abstract
Novel species of fungi described in this study include those from various countries as follows: Australia: Apiognomonia lasiopetali on Lasiopetalum sp., Blastacervulus eucalyptorum on Eucalyptus adesmophloia, Bullanockia australis (incl. Bullanockia gen. nov.) on Kingia australis, Caliciopsis eucalypti on Eucalyptus marginata, Celerioriella petrophiles on Petrophile teretifolia, Coleophoma xanthosiae on Xanthosia rotundifolia, Coniothyrium hakeae on Hakea sp., Diatrypella banksiae on Banksia formosa, Disculoides corymbiae on Corymbia calophylla, Elsinoë eelemani on Melaleuca alternifolia, Elsinoë eucalyptigena on Eucalyptus kingsmillii, Elsinoë preissianae on Eucalyptus preissiana, Eucasphaeria rustici on Eucalyptus creta, Hyweljonesia queenslandica (incl. Hyweljonesia gen. nov.) on the cocoon of an unidentified microlepidoptera, Mycodiella eucalypti (incl. Mycodiella gen. nov.) on Eucalyptus diversicolor, Myrtapenidiella sporadicae on Eucalyptus sporadica, Neocrinula xanthorrhoeae (incl. Neocrinula gen. nov.) on Xanthorrhoea sp., Ophiocordyceps nooreniae on dead ant, Phaeosphaeriopsis agavacearum on Agave sp., Phlogicylindrium mokarei on Eucalyptus sp., Phyllosticta acaciigena on Acacia suaveolens, Pleurophoma acaciae on Acacia glaucoptera, Pyrenochaeta hakeae on Hakea sp., Readeriella lehmannii on Eucalyptus lehmannii, Saccharata banksiae on Banksia grandis, Saccharata daviesiae on Daviesia pachyphylla, Saccharata eucalyptorum on Eucalyptus bigalerita, Saccharata hakeae on Hakea baxteri, Saccharata hakeicola on Hakea victoria, Saccharata lambertiae on Lambertia ericifolia, Saccharata petrophiles on Petrophile sp., Saccharata petrophilicola on Petrophile fastigiata, Sphaerellopsis hakeae on Hakea sp., and Teichospora kingiae on Kingia australis.Brazil: Adautomilanezia caesalpiniae (incl. Adautomilanezia gen. nov.) on Caesalpina echinata, Arthrophiala arthrospora (incl. Arthrophiala gen. nov.) on Sagittaria montevidensis, Diaporthe caatingaensis (endophyte from Tacinga inamoena), Geastrum ishikawae on sandy soil, Geastrum pusillipilosum on soil, Gymnopus pygmaeus on dead leaves and sticks, Inonotus hymenonitens on decayed angiosperm trunk, Pyricularia urashimae on Urochloa brizantha, and Synnemellisia aurantia on Passiflora edulis. Chile: Tubulicrinis australis on Lophosoria quadripinnata.France: Cercophora squamulosa from submerged wood, and Scedosporium cereisporum from fluids of a wastewater treatment plant. Hawaii: Beltraniella acaciae, Dactylaria acaciae, Rhexodenticula acaciae, Rubikia evansii and Torula acaciae (all on Acacia koa).India: Lepidoderma echinosporum on dead semi-woody stems, and Rhodocybe rubrobrunnea from soil. Iran: Talaromyces kabodanensis from hypersaline soil. La Réunion: Neocordana musarum from leaves of Musa sp. Malaysia: Anungitea eucalyptigena on Eucalyptus grandis × pellita, Camptomeriphila leucaenae (incl. Camptomeriphila gen. nov.) on Leucaena leucocephala, Castanediella communis on Eucalyptus pellita, Eucalyptostroma eucalypti (incl. Eucalyptostroma gen. nov.) on Eucalyptus pellita, Melanconiella syzygii on Syzygium sp., Mycophilomyces periconiae (incl. Mycophilomyces gen. nov.) as hyperparasite on Periconia on leaves of Albizia falcataria, Synnemadiella eucalypti (incl. Synnemadiella gen. nov.) on Eucalyptus pellita, and Teichospora nephelii on Nephelium lappaceum.Mexico: Aspergillus bicephalus from soil. New Zealand: Aplosporella sophorae on Sophora microphylla, Libertasomyces platani on Platanus sp., Neothyronectria sophorae (incl. Neothyronectria gen. nov.) on Sophora microphylla, Parastagonospora phoenicicola on Phoenix canariensis, Phaeoacremonium pseudopanacis on Pseudopanax crassifolius, Phlyctema phoenicis on Phoenix canariensis, and Pseudoascochyta novae-zelandiae on Cordyline australis.Panama: Chalara panamensis from needle litter of Pinus cf. caribaea. South Africa: Exophiala eucalypti on leaves of Eucalyptus sp., Fantasmomyces hyalinus (incl. Fantasmomyces gen. nov.) on Acacia exuvialis, Paracladophialophora carceris (incl. Paracladophialophora gen. nov.) on Aloe sp., and Umthunziomyces hagahagensis (incl. Umthunziomyces gen. nov.) on Mimusops caffra.Spain: Clavaria griseobrunnea on bare ground in Pteridium aquilinum field, Cyathus ibericus on small fallen branches of Pinus halepensis, Gyroporus pseudolacteus in humus of Pinus pinaster, and Pseudoascochyta pratensis (incl. Pseudoascochyta gen. nov.) from soil. Thailand: Neoascochyta adenii on Adenium obesum, and Ochroconis capsici on Capsicum annuum. UK: Fusicolla melogrammae from dead stromata of Melogramma campylosporum on bark of Carpinus betulus. Uruguay: Myrmecridium pulvericola from house dust. USA: Neoscolecobasidium agapanthi (incl. Neoscolecobasidium gen. nov.) on Agapanthus sp., Polyscytalum purgamentum on leaf litter, Pseudopithomyces diversisporus from human toenail, Saksenaea trapezispora from knee wound of a soldier, and Sirococcus quercus from Quercus sp. Morphological and culture characteristics along with DNA barcodes are provided.
Collapse
Affiliation(s)
- P.W. Crous
- CBS-KNAW Fungal Biodiversity Centre, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
- Department of Microbiology and Plant Pathology, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, P. Bag X20, Pretoria 0028, South Africa
| | - M.J. Wingfield
- Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria 0002, South Africa
| | - T.I. Burgess
- Centre for Phytophthora Science and Management, Murdoch University, 90 South Street, Murdoch, WA 6150, Australia
| | - G.E.St.J. Hardy
- Centre for Phytophthora Science and Management, Murdoch University, 90 South Street, Murdoch, WA 6150, Australia
| | - C. Crane
- Department of Parks and Wildlife, Vegetation Health Service, Locked Bag 104, Bentley Delivery Centre, Bentley, WA 6983, Australia
| | - S. Barrett
- Department of Parks and Wildlife Albany District, 120 Albany Highway, Albany, WA 6330, Australia
| | - J.F. Cano-Lira
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - J.J. Le Roux
- Centre for Invasion Biology, Department of Botany & Zoology, Stellenbosch University, Matieland 7602, South Africa
| | - R. Thangavel
- Plant Health & Environment Laboratory, Ministry for Primary Industries, Manatū Ahu Matua, 231 Morrin Road, St Johns, Auckland 1072, P.O. Box 2095, Auckland 1140, New Zealand
| | - J. Guarro
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - A.M. Stchigel
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - M.P. Martín
- Departamento de Micología, Real Jardín Botánico-CSIC, Plaza de Murillo 2, 28014 Madrid, Spain
| | - D.S. Alfredo
- Pós-graduação em Sistemática e Evolução, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
| | - P.A. Barber
- ArborCarbon, 1 City Farm Place, East Perth, Western Australia, 6004 Australia
| | - R.W. Barreto
- Departamento de Fitopatologia, Universidade Federal de Viçosa, Viçosa, 36570-900, MG, Brazil
| | - I.G. Baseia
- Departamento de Botânica e Zoologia, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
| | - J. Cano-Canals
- I.E.S Gabriel Ferrater i Soler, Ctra. de Montblanc, 5-9, 43206 Reus, Tarragona, Spain
| | - R. Cheewangkoon
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - R.J. Ferreira
- Pós-graduação em Biologia de Fungos, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
| | - J. Gené
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - C. Lechat
- Ascofrance, 64 route de Chizé, 79360 Villiers en Bois, France
| | - G. Moreno
- Departamento de Ciencias de la Vida (Unidad Docente de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - F. Roets
- Department of Conservation Ecology and Entomology, Stellenbosch University, South Africa
| | - R.G. Shivas
- Department of Agriculture and Fisheries, GPO Box 267, Brisbane 4001, Queensland, Australia
| | - J.O. Sousa
- Departamento de Botânica e Zoologia, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
| | - Y.P. Tan
- Department of Agriculture and Fisheries, GPO Box 267, Brisbane 4001, Queensland, Australia
| | - N.P. Wiederhold
- Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, Texas 78229-3900, USA
| | - S.E. Abell
- Australian Tropical Herbarium, James Cook University, PO Box 6811, Cairns 4870, Queensland, Australia
| | - T. Accioly
- Departamento de Botânica e Zoologia, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
| | - J.L. Albizu
- Aranzadi Society of Sciences, Mycology section, Zorroagagaina 11, P.C. 200014, Donostia-San Sebastián, Spain
| | - J.L. Alves
- Departamento de Fitopatologia, Universidade Federal de Viçosa, Viçosa, 36570-900, MG, Brazil
| | - Z.I. Antoniolli
- Programa de Pós-graduação em Ciência do Solo, CCR, Universidade Federal de Santa Maria, Av. Roraima n°1000, Campus, Bairro Camobi, CEP 97105-900, Santa Maria, RS, Brasil
| | - N. Aplin
- 21 Shetland Close, Pound Hill, Crawley, West Sussex RH10 7YZ, England, UK
| | - J. Araújo
- Center of Infectious Disease Dynamics, Millennium Science Complex, University Park Campus, Pennsylvania State University, USA
| | - M. Arzanlou
- Plant Protection Department, Faculty of Agriculture, University of Tabriz, P.O. Box 5166614766, Tabriz, Iran
| | - J.D.P. Bezerra
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - J.-P. Bouchara
- GEIHP - EA 3142, Université d’Angers, Institut de Biologie en Santé PBH-IRIS CHU, 4 Rue Larrey, 49933 Angers Cedex 9, France
| | - J.R. Carlavilla
- Departamento de Ciencias de la Vida (Unidad Docente de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - A. Castillo
- Departamento de Ciencias de la Vida (Unidad Docente de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - V.L. Castroagudín
- UNESP-University of São Paulo State, Av. Brasil no. 56, 15385-000, Ilha Solteira, São Paulo, Brazil
| | - P.C. Ceresini
- UNESP-University of São Paulo State, Av. Brasil no. 56, 15385-000, Ilha Solteira, São Paulo, Brazil
| | | | - G. Coelho
- Departamento de Fundamentos da Educação, CCR, Universidade Federal de Santa Maria, Av. Roraima n°1000, Campus, Bairro Camobi, CEP 97105-900, Santa Maria, RS, Brasil
| | - V.R.M. Coimbra
- Departamento de Micologia, Centro de Ciências Biológicas, Universidade Federal de Pernambuco, Av. Prof. Nelson Chaves, s/n, 50670-901 Recife, Pernambuco, Brazil
| | - L.A. Costa
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina s/n, Novo Horizonte, 44036-900, Feira de Santana, BA, Brazil
| | - K.C. da Cunha
- Dermatology Laboratory (SML), University Hospital of Geneva, Rue Gabrielle Perret-Gentil 4, 1205 Genève, Geneva, Switzerland
| | - S.S. da Silva
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina s/n, Novo Horizonte, 44036-900, Feira de Santana, BA, Brazil
| | - R. Daniel
- Elizabeth Macarthur Agricultural Institute, Department of Primary Industries, Private Bag 4008, Narellan 2567, Australia
| | - Z.W. de Beer
- Department of Microbiology and Plant Pathology, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, P. Bag X20, Pretoria 0028, South Africa
| | - M. Dueñas
- Departamento de Micología, Real Jardín Botánico-CSIC, Plaza de Murillo 2, 28014 Madrid, Spain
| | - J. Edwards
- AgriBio Centre for AgriBiosciences, Department of Economic Development, Jobs, Transport and Resources, 5 Ring Road, LaTrobe University, Bundoora, Victoria 3083 Australia
| | - P. Enwistle
- North East Agricultural Services, McLeans Ridges 2480, NSW, Australia
| | - P.O. Fiuza
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina s/n, Novo Horizonte, 44036-900, Feira de Santana, BA, Brazil
| | | | - D. García
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - T.B. Gibertoni
- Departamento de Micologia, Centro de Ciências Biológicas, Universidade Federal de Pernambuco, Av. Prof. Nelson Chaves, s/n, 50670-901 Recife, Pernambuco, Brazil
| | - S. Giraud
- GEIHP - EA 3142, Université d’Angers, Institut de Biologie en Santé PBH-IRIS CHU, 4 Rue Larrey, 49933 Angers Cedex 9, France
| | - M. Guevara-Suarez
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - L.F.P. Gusmão
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina s/n, Novo Horizonte, 44036-900, Feira de Santana, BA, Brazil
| | - S. Haituk
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - M. Heykoop
- Departamento de Ciencias de la Vida (Unidad Docente de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - Y. Hirooka
- Biodiversity (Mycology), Agriculture and Agri-Food Canada, Ottawa, ON, K1A 0C6, Canada; Department of Clinical Plant Science, Faculty of Bioscience, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo, Japan
| | - T.A. Hofmann
- Herbarium UCH, Mycological Research Center (CIMi), Autonomous University of Chiriquí (UNACHI), 0427, David, Chiriquí Province, Panama
| | - J. Houbraken
- CBS-KNAW Fungal Biodiversity Centre, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| | - D.P. Hughes
- Center of Infectious Disease Dynamics, Millennium Science Complex, University Park Campus, Pennsylvania State University, USA
| | - I. Kautmanová
- Slovak National Museum-Natural History Museum, P.O. Box 13, 810 06 Bratislava, Slovakia
| | - O. Koppel
- Biodiversity (Mycology), Agriculture and Agri-Food Canada, Ottawa, ON, K1A 0C6, Canada; Department of Biology, University of Ottawa, 30 Marie-Curie, Ottawa, ON K1N 6N5, Canada
| | - O. Koukol
- Department of Botany, Faculty of Science, Charles University, Benátská 2, CZ-12801, Praha 2, Czech Republic
| | - E. Larsson
- Department of Biological and Environmental Sciences, University of Gothenburg, Box 463, 405 30 Göteborg, Sweden
| | - K.P.D. Latha
- Department of Botany, University of Calicut, Kerala, 673 635, India
| | - D.H. Lee
- Department of Genetics, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, P. Bag X20, Pretoria 0002, South Africa
| | - D.O. Lisboa
- Departamento de Fitopatologia, Universidade Federal de Viçosa, Viçosa, 36570-900, MG, Brazil
| | - W.S. Lisboa
- Departamento de Fitopatologia, Universidade Federal de Viçosa, Viçosa, 36570-900, MG, Brazil
| | - Á. López-Villalba
- Departamento de Ciencias de la Vida (Unidad Docente de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - J.L.N. Maciel
- Brazilian Agriculture Research Corporation-Wheat (EMBRAPA-Trigo), Caixa Postal 3081, Rodovia BR-285 Km 294, 99050-970 Passo Fundo, Rio Grande do Sul, Brazil
| | - P. Manimohan
- Department of Botany, University of Calicut, Kerala, 673 635, India
| | - J.L. Manjón
- Departamento de Ciencias de la Vida (Unidad Docente de Botánica), Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain
| | - S. Marincowitz
- Department of Microbiology and Plant Pathology, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, P. Bag X20, Pretoria 0028, South Africa
| | - T.S. Marney
- Department of Agriculture and Fisheries, GPO Box 267, Brisbane 4001, Queensland, Australia
| | - M. Meijer
- CBS-KNAW Fungal Biodiversity Centre, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| | - A.N. Miller
- University of Illinois Urbana-Champaign, Illinois Natural History Survey, 1816 South Oak Street, Champaign, Illinois, 61820, USA
| | - I. Olariaga
- University of the Basque Country (UPV/EHU), Apdo. 644, E-48080 Bilbao, Spain
| | - L.M. Paiva
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - M. Piepenbring
- Department of Mycology, Cluster for Integrative Fungal Research (IPF), Institute for Ecology, Evolution and Diversity, Goethe University, Max-von-Laue-Str. 13, DE-60438 Frankfurt am Main, Germany
| | | | - K.N.A. Raj
- Department of Botany, University of Calicut, Kerala, 673 635, India
| | - H.A. Raja
- University of North Carolina, Department of Chemistry and Biochemistry, Greensboro, North Carolina, 27402, USA
| | - A. Rougeron
- GEIHP - EA 3142, Université d’Angers, Institut de Biologie en Santé PBH-IRIS CHU, 4 Rue Larrey, 49933 Angers Cedex 9, France
| | - I. Salcedo
- University of the Basque Country (UPV/EHU), Apdo. 644, E-48080 Bilbao, Spain
| | - R. Samadi
- Plant Protection Department, Faculty of Agriculture, University of Tabriz, P.O. Box 5166614766, Tabriz, Iran
| | - T.A.B. Santos
- Departamento de Ciências Biológicas, Universidade Estadual de Feira de Santana, Av. Transnordestina s/n, Novo Horizonte, 44036-900, Feira de Santana, BA, Brazil
| | - K. Scarlett
- Faculty of Agriculture and Environment, The University of Sydney, Sydney 2006, Australia
| | - K.A. Seifert
- Biodiversity (Mycology), Agriculture and Agri-Food Canada, Ottawa, ON, K1A 0C6, Canada; Department of Biology, University of Ottawa, 30 Marie-Curie, Ottawa, ON K1N 6N5, Canada
| | - L.A. Shuttleworth
- Elizabeth Macarthur Agricultural Institute, Department of Primary Industries, Private Bag 4008, Narellan 2567, Australia
| | - G.A. Silva
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - M. Silva
- Departamento de Fitopatologia, Universidade Federal de Viçosa, Viçosa, 36570-900, MG, Brazil
| | - J.P.Z. Siqueira
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - C.M. Souza-Motta
- Departamento de Micologia Prof. Chaves Batista, Universidade Federal de Pernambuco, Recife, Brazil
| | - S.L. Stephenson
- Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas 72701, USA
| | - D.A. Sutton
- Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, Texas 78229-3900, USA
| | - N. Tamakeaw
- Department of Entomology and Plant Pathology, Faculty of Agriculture, Chiang Mai University, Chiang Mai 50200, Thailand
| | - M.T. Telleria
- Departamento de Micología, Real Jardín Botánico-CSIC, Plaza de Murillo 2, 28014 Madrid, Spain
| | - N. Valenzuela-Lopez
- Mycology Unit, Medical School and IISPV, Universitat Rovira i Virgili (URV), Sant Llorenç 21, 43201 Reus, Tarragona, Spain
| | - A. Viljoen
- Department of Plant Pathology, University of Stellenbosch, Private Bag X1, Stellenbosch 7602, South Africa
| | - C.M. Visagie
- Biodiversity (Mycology), Agriculture and Agri-Food Canada, Ottawa, ON, K1A 0C6, Canada; Department of Biology, University of Ottawa, 30 Marie-Curie, Ottawa, ON K1N 6N5, Canada
| | - A. Vizzini
- Department of Life Sciences and Systems Biology, University of Torino, Viale P.A. Mattioli 25, I-10125 Torino, Italy
| | - F. Wartchow
- Departamento de Sistemática e Ecologia, Centro de Ciências Exatas e da Natureza, Universidade Federal da Paraíba, 58051-900 João Pessoa, Paraíba, Brazil
| | - B.D. Wingfield
- Department of Genetics, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, P. Bag X20, Pretoria 0002, South Africa
| | - E. Yurchenko
- Department of Biotechnology, Paleski State University, Dnyaprouskai flatylii str. 23, BY-225710, Pinsk, Belarus
| | - J.C. Zamora
- Departamento de Biología Vegetal II, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain
| | - J.Z. Groenewald
- CBS-KNAW Fungal Biodiversity Centre, P.O. Box 85167, 3508 AD Utrecht, The Netherlands
| |
Collapse
|
45
|
Park P, Koay E, Yang J, Suh Y, Das P, Crane C, Beddar S. EP-1901: Patient-specific deformable image registration quality assurance based on feature points. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33152-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys 2015; 94:554-60. [PMID: 26725729 DOI: 10.1016/j.ijrobp.2015.10.062] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 09/29/2015] [Accepted: 10/29/2015] [Indexed: 11/18/2022]
Abstract
PURPOSE To confirm whether a previously observed association between RECQ1 A159C variant and clinical outcome of resectable pancreatic cancer patients treated with preoperative chemoradiation is reproducible in another patient population prospectively treated with postoperative chemoradiation. METHODS AND MATERIALS Patients were selected, according to tissue availability, from eligible patients with resected pancreatic cancer who were enrolled on the NRG Oncology Radiation Therapy Oncology Group 9704 trial of 5-fluorouacil (5-FU)-based chemoradiation preceded and followed by 5-FU or gemcitabine. Deoxyribonucleic acid was extracted from paraffin-embedded tissue sections, and genotype was determined using the Taqman method. The correlation between genotype and overall survival was analyzed using a Kaplan-Meier plot, log-rank test, and multivariate Cox proportional hazards models. RESULTS In the 154 of the study's 451 eligible patients with evaluable tissue, genotype distribution followed Hardy-Weinberg equilibrium (ie, 37% had genotype AA, 43% AC, and 20% CC). The RECQ1 variant AC/CC genotype carriers were associated with being node positive compared with the AA carrier (P=.03). The median survival times (95% confidence interval [CI]) for AA, AC, and CC carriers were 20.6 (16.3-26.1), 18.8 (14.2-21.6), and 14.2 (10.3-21.0) months, respectively. On multivariate analysis, patients with the AC/CC genotypes were associated with worse survival than patients with the AA genotype (hazard ratio [HR] 1.54, 95% CI 1.07-2.23, P=.022). This result seemed slightly stronger for patients on the 5-FU arm (n=82) (HR 1.64, 95% CI 0.99-2.70, P=.055) than for patients on the gemcitabine arm (n=72, HR 1.46, 95% CI 0.81-2.63, P=.21). CONCLUSIONS Results of this study suggest that the RECQ1 A159C genotype may be a prognostic or predictive factor for resectable pancreatic cancer patients who are treated with adjuvant 5-FU before and after 5-FU-based chemoradiation. Further study is needed in patients treated with gemcitabine to determine whether an association exists.
Collapse
Affiliation(s)
- Donghui Li
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
| | - Jennifer Moughan
- NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
| | - Christopher Crane
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - John P Hoffman
- Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - William F Regine
- Department of Radiation Oncology, University of Maryland, Baltimore, Maryland
| | | | - Howard Safran
- Brown University Oncology Group, Providence, Rhode Island
| | - Chang Liu
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Ping Chang
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Gary M Freedman
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Kathryn A Winter
- NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
| | - Chandan Guha
- Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
| | | |
Collapse
|
47
|
Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng C. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist 2015; 20:1247-52. [PMID: 26382740 DOI: 10.1634/theoncologist.2015-0091] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Accepted: 07/22/2015] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND The incidence of anal carcinoma in the U.S. continues to increase steadily, and infection with the human papillomavirus (HPV) is an established risk factor for the development of anal carcinoma. However, the clinicopathologic characteristics of patients with metastatic squamous cell carcinoma of the anal canal according to HPV status have not yet been defined. MATERIALS AND METHODS The records of patients treated for metastatic squamous cell carcinoma of the anal canal at the MD Anderson Cancer Center from June 2005 to August 2013 were reviewed. The patients were tested for the presence of HPV DNA by in situ hybridization and/or the p16 oncoprotein by immunohistochemistry. Associations between the presence of HPV and clinicopathologic attributes were measured. RESULTS Of the 72 patients reviewed, 68 tumors (94%) had detectable HPV. Patients with HPV-negative tumors were more likely to be of nonwhite ethnicity (odds ratio, 8.7) and have a strong (>30 pack-year) tobacco history (odds ratio, 8.7). A trend toward improved survival from the time of diagnosis of metastatic disease was noted among patients with HPV-positive tumors. CONCLUSION Most patients with metastatic anal cancer had detectable HPV, with differences in tobacco history and ethnicity detected according to HPV status. The high frequency of HPV positivity for patients with metastatic anal cancer has important implications for novel immunotherapy treatment approaches, including ongoing clinical trials with immune checkpoint blockade agents using antibodies targeting the programmed death-1 receptor. IMPLICATIONS FOR PRACTICE Previous studies investigating the clinical features of patients with anal cancer focused on those with early-stage disease. The present study characterizes, for the first time, clinical and pathological features according to human papillomavirus (HPV) status for patients with metastatic anal cancer. A high frequency of HPV-positive tumors and correlations between HPV status and both ethnicity and tobacco history was found. No standard-of-care therapy is available for patients with metastatic anal cancer, and most receive cytotoxic chemotherapy. The high prevalence of HPV in the current population generates optimism for ongoing clinical trials investigating the role of immune checkpoint blockade agents as a novel treatment approach for this disease.
Collapse
Affiliation(s)
- Van K Morris
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Asif Rashid
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Miguel Rodriguez-Bigas
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Prajnan Das
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - George Chang
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Aki Ohinata
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jane Rogers
- Department of Clinical Pharmacy Services, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Christopher Crane
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Robert A Wolff
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Cathy Eng
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
48
|
Suh Y, Hui C, Robertson D, Pan T, Das P, Crane C, Beddar S. SU-E-J-157: Comparison Between Internal Respiratory Signal and External Respiratory Signal in 4D CT. Med Phys 2015. [DOI: 10.1118/1.4924242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
49
|
Suh Y, Crane C, Krishnan S, Das P, Koay E, Beddar S. SU-E-J-33: Comparison Between Soft Tissue Alignment and Bony Alignment for Pancreatic Cancer Radiotherapy. Med Phys 2015. [DOI: 10.1118/1.4924120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
50
|
Mars B, Heron J, Crane C, Hawton K, Lewis G, Macleod J, Tilling K, Gunnell D. Clinical and social outcomes of adolescent self harm: population based birth cohort study. BMJ 2014. [DOI: 10.1136/bmj.g5954 (published 22 october 2014)] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|